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Abstract
Objective: 1) Estimate the prevalence of self-reported ADHD symptoms in sample of youth
(grades 9-12) in Ontario schools, by sex; and 2) Assess the relationship between ADHD
symptoms and substance use (alcohol, tobacco cigarettes, cannabis, stimulants) by sex,
controlling for socio-economic status, internalizing and externalizing problems.
Methods: Data from 2015 and 2017 (n = 6,923) Centre for Addiction and Mental Health Ontario
Student Drug Use and Health Survey, included self-reports of ADHD symptomatology and
substance use. Statistical analyses included bivariate tables and multinomial regressions.
Results: Prevalence for ADHD symptoms was 20.22%, 95% CI [18.52, 22.03] (males = 16.42%,
95% CI [14.66, 18.34]; females = 24.06%, 95% CI [21.79, 26.49]). Females reporting ADHD
symptoms showed increased risk of tobacco cigarette use and cannabis use when accounting for
covariates.

Conclusion: The ADHD symptom screener found a large proportion of self-reported ADHD
symptoms, especially in females. ADHD symptoms were associated with few substances.

Keywords
ADHD, Adolescent, Ontario, Centre for Addiction and Mental Health, Ontario Student Drug Use
and Health Survey, Prevalence, Sex, Alcohol, Tobacco Cigarettes, Cannabis, Stimulants,
Substance Use, Socio-economic Status, Internalizing Problem, Externalizing problem
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Summary for Lay Audience
The goal of this current study was to present the prevalence of ADHD symptoms in a sample of
youth in Ontario and to assess the relationship between ADHD symptoms and substance use.
Substances that were examined include alcohol, tobacco cigarettes, cannabis and stimulants.
Stimulants included cocaine, crack-cocaine, ecstasy, and methamphetamine. It is posited that
socio-economic status and social, emotional, and behavioural problems play a part in the
relationship between ADHD symptoms and substance use. Social, emotional, and behavioural
problems include internalizing problems (refers to the internal psyche and include depression,
anxiety, etc.) and externalizing problems (distress that results in outward behaviour and include
aggressive and delinquent behaviours).
Methods include the use of two cycles of survey data from schools across Ontario. The age
group of interest includes students that were in grade 9 through 12 at the time of the survey.
Sampling weights insured that results from the study reflected students that make up the Ontario
population. Importantly, the measurement used to assess ADHD symptoms was a self-report
symptom checklist, not a full diagnostic assessment administered by a physician.
The overall prevalence for self-reported ADHD symptoms was 20.22%, with 16.42% of males
self-reporting ADHD symptoms and 24.06% of females self-reporting ADHD symptoms. These
percentages are high compared to studies that used actual diagnostic measurements; however,
these percentages are comparable to studies that used the same symptom checklist that was used
in this current study. Without the consideration of socio-economic status and social, emotional,
and behavioural problems, it would seem as if ADHD symptoms were a risk factor for alcohol
use, tobacco cigarette use, cannabis use, and stimulant use for females. For males, the findings
suggest that ADHD symptoms were a risk factor for tobacco cigarette use and stimulant use.
However, after controlling for socio-economic status and social, emotional, and behavioural
problems, it is evident that ADHD symptoms only presented an increased risk for tobacco
cigarette use and cannabis use for females. Due to the limitations, findings should be interpreted
cautiously. Future studies should explore what is being captured by the self-report symptom
checklist used in this current study.
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Chapter 1

1

Summary

1.1 Background
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that
significantly influences executive functioning and development (APA, 2013). According to the
Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5), a diagnosis of
ADHD includes six (or five for people over 17 years) of the nine symptoms of inattention and
six (or five for people over 17 years) of the nine symptoms of hyperactivity-impulsivity (APA,
2013). ADHD is among the most frequently diagnosed mental health disorders during childhood
and adolescence (Simon et al., 2009). In Canada, seven studies have assessed the prevalence of
ADHD or ADHD symptoms (age range 1 to 24 years) (Brault & Lacourse, 2012; Brownell &
Yogendran, 2001; Georgiades et al., 2019; Hauck, Lau, Wing, Kurdyak, & Tu, 2017; McMartin,
Kingsbury, Dykxhoorn, & Colman, 2014; Szatmari, Boyle, & Offord, 1989; Vasiliadis et al.,
2017). Of the seven studies, general prevalence estimates have ranged from 1.5% (Brownell &
Yogendran, 2001) to 10.49% (Georgiades et al., 2019). International studies using symptom
checklists have found much higher prevalence of self-reported ADHD symptoms, with
prevalence as high as 20.90% (Sonnby, Åslund, Leppert, & Nilsson, 2011). This variation in
ADHD estimates may be due to differences in measures (use of symptom checklists rather than
assessment of administrative medical claims for actual ADHD diagnoses), who provided the
information (clinician, parent, teacher, or youth), and sociodemographic information (age) of the
children and youth being assessed for ADHD (Skounti, Philalithis, & Galanakis, 2007).
Additionally, the literature indicates that ADHD symptoms may be expressed differently by
males and females. Disruptive behaviours, such as aggression, disciplinary violations, and other
behaviours violating social norms (which are easily observed by parents and teachers) may be a
reason why males with ADHD are more likely to be identified than females with ADHD (Wang
et al., 2017). Conversely, females with ADHD are less likely to have disruptive behaviour
disorders and are more likely to report higher prevalence of symptoms of inattention, which are
more covert than those of hyperactivity and impulsivity (Biederman & Faraone, 2004).
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ADHD is associated with health risk behaviours, such as substance use (Klassen, Bilkey,
Katzman, & Chokka, 2012). Literature has shown different relationships between ADHD and
substance use depending on the substance. For example, the literature indicates conflicting
results for the relationships between ADHD symptoms and alcohol (Elkins et al., 2018;
Fergusson, Horwood, & Ridder, 2007; Flory, Milich, Lynam, Leukefeld, & Clayton, 2003;
Galéra, Bouvard, Messiah, & Fombonne, 2008; Sihvola et al., 2011; Upadhyaya & Carpenter,
2008), and ADHD symptoms and cannabis use (Elkins et al., 2018; Fergusson et al., 2007; Flory
et al., 2003; Galéra et al., 2008; Upadhyaya & Carpenter, 2008), although the majority of studies
indicate that ADHD symptoms are significantly associated with tobacco cigarette use (Fergusson
et al., 2007; Flory et al., 2003; Galéra et al., 2013; Kollins, McClernon, & Fuemmeler, 2005;
Sihvola et al., 2011; Upadhyaya & Carpenter, 2008). Additionally, some studies have found that
the relationships between ADHD and substance use may vary by sex. For example, some
research has found a significant relationship between ADHD symptoms and alcohol use (Elkins
et al., 2018; Sihvola et al., 2011) and daily tobacco cigarette use (Galéra, Fombonne, Chastang,
& Bouvard, 2005) in females but not in males. Yet another study found a relationship between
ADHD symptoms and regular use of cannabis in males but not regular use of cannabis in females
or lifetime cannabis use (Galéra et al., 2008). Hence, the literature provides conflicting evidence
on the relationship between ADHD and different substances and on differences in use of
different substances by males and females with ADHD symptoms.
Moreover, the majority of studies examining the relationship between ADHD symptoms and
substance use have examined the commonly popular substances that children and youth use:
alcohol (Elkins et al., 2018; Fergusson et al., 2007; Flory et al., 2003; Galéra et al., 2008; Sihvola
et al., 2011; Upadhyaya & Carpenter, 2008), tobacco cigarettes (Fergusson et al., 2007; Flory et
al., 2003; Galéra et al., 2005; Galéra, 2013; Kollins et al., 2005; Sihvola et al., 2011; Upadhyaya
& Carpenter, 2008) and cannabis (Elkins et al., 2018; Fergusson et al., 2007; Flory et al., 2003;
Galéra et al., 2008; Upadhyaya & Carpenter, 2008). Few have examined cocaine (Galéra et al.,
2013; Lambert & Hartsough, 1998) and no studies using youth samples have examined increased
risk of crack-cocaine, methamphetamine, or ecstasy in relation to ADHD symptoms.
Socioeconomic status (SES) is thought to be related to both ADHD and substance use.
According to a national health interview survey (data from 2011-2013) in the United States,
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children and youth living in poverty have the highest rate of ADHD (CDC/NCHS, 2013). Other
studies have suggested that research is inconsistent on whether the direction of the relationship
between SES and substance use is positive or negative (Hamilton, Maas, Boak, & Mann, 2014).
For these reasons, it is important to examine SES when assessing the relationship between
ADHD and substance use, to observe if controlling for SES changes the relationship between
ADHD and substance use.
An examination of ADHD and substance use should not be conducted without considering
internalizing problems (i.e., depression, anxiety) and externalizing problems (i.e., oppositional
defiant disorder, conduct disorder (CD)) since internalizing and externalizing problems have
been identified as co-occurring problems with both ADHD and substance use (Jacob, et al.,
2014; Lee, Humphreys, Flory, Liu, & Glass, 2011). Because of the co-occurrence of
internalizing and externalizing problems with ADHD and substance use, Lee et al. (2011)
strongly recommends that internalizing and externalizing problems be included in analyses
examining ADHD and substance use.

1.2 Objectives
To address the current knowledge gaps, this study will use population-based data of Ontario
youth to: 1) estimate the prevalence of self-reported ADHD symptoms in a representative sample
of youth (grades 9-12) in Ontario schools, separately for males and females; and 2) assess the
relationship between self-reported ADHD symptoms and substance use among males and
females, while controlling for SES, internalizing problems, and externalizing problems.

1.3 Thesis Structure
This thesis includes five chapters. Chapter 2 provides an overview of the current literature on
ADHD in children and youth and on the relationships between ADHD and substance use. This
literature review provides the study rationale and informs the objectives. Chapter 3 provides
information on the methods, including the data source, the study population, measures and the
data analytic strategy. Chapter 4 presents the results of the study and Chapter 5 provides a
discussion of the findings, the strengths and weaknesses of the study, and suggestions for future
research.
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Chapter 2

2

Literature Review

2.1 Definition of ADHD
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that
significantly influences executive functioning and development (APA, 2013). People with
ADHD show a persistent pattern of inattention and/or hyperactivity-impulsivity. Since its clinical
emergence in 1902 (Still, 1902), ADHD has been designated by a myriad of terms including:
minimal brain damage, hyperkinetic syndrome, hyperactivity and attention-deficit disorder
(ADD) among others. In DSM-II, ADHD was termed Hyperkinetic Reaction of Childhood,
which focused primarily on symptoms of excessive motor activity (APA, 1968). In DSM-III,
ADHD was markedly re-conceptualized with a focus on problems with attention, impulsivity,
and hyperactivity; in this version, the disorder was renamed attention deficit disorder (ADD)
(with and without hyperactivity) (APA, 1980). The term ADHD was finally introduced in DSMIII-R with the elimination of ADD without hyperactivity (APA, 1987). With DSM-IV, the term
ADHD was retained, along with the introduction of the three subtypes: combined presentation,
predominantly inattentive presentation, and predominantly hyperactive-impulsive presentation
(APA, 1994). However, because symptoms can change over time, the presentation of ADHD
may be subject to change. Previous adaptations of ADHD stressed a narrower focus on motor
activity; however, the current conceptualization emphasizes difficulty with sustained attention
and deficits in the regulation of cognitive functioning (Faraone et al., 2000).
The current diagnostic criteria for ADHD in North America are outlined by the Diagnostic and
Statistical Manual of Mental Disorders Version 5 (DSM-5). To be diagnosed, six or more of the
symptoms of inattention or hyperactivity-impulsivity must cause impairment for children and
youth up to age 16 years, or five or more symptoms for youth age 17 years and older. These
symptoms must have been present for at least six months. Symptoms of inattention include
examples such as, often fails to give close attention to details or makes careless mistakes, often
has trouble holding attention on tasks or play activities, often does not seem to listen when talked
to directly, and often has trouble organizing tasks and activities. Symptoms of hyperactivity and
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impulsivity include examples such as, often fidgets with or taps hands or feet, or squirms around,
often leaves seat in situations when remaining seated is expected, often talks excessively, and
often has trouble waiting their turn. These symptoms must not be better explained by another
mental disorder such as a mood disorder. In addition, several inattentive or hyperactiveimpulsive symptoms must be present before the age of 12 and several symptoms must be present
in two or more settings such as at home and school. Lastly, there must be clear evidence that
these symptoms reduce the quality of school or social functioning (APA, 2013).
The evolution of the nomenclature for the disorder from DSM-II to DSM-5 has broadened the
case definition, resulting in more individuals being diagnosed with ADHD. For example,
criterion A (ADHD symptoms) changed with a reduction from six to five in the minimum
number of symptoms in either symptom domain required for older adolescents and adults
(Epstein & Loren, 2013). Criterion B (age of onset) changed from onset of symptoms and
impairments before age seven to onset of symptoms before age 12. Criterion C (pervasiveness)
was changed from evidence of impairment to evidence of symptoms in two or more
settings. Criterion D (impairment) now requires that functional impairments only need to “reduce
the quality of social, academic or occupational functioning” instead of requiring that they be
“clinically significant.” With changes in each criterion, it is evident that ADHD and the
requirements for diagnosis of this disorder has evolved over time.

2.2 Prevalence Estimates of ADHD and ADHD Symptoms in
Canada
In order to assess the prevalence of ADHD in Canada, PubMed was searched through December
2019. The following keywords were searched: ADHD prevalence, Canada, and youth. Keywords
were combined using the Boolean variables “AND”. The search for humans was specified under
the species category. This search stream yielded a total of 293 results on PubMed. Titles and
abstracts were read and compared with inclusion and exclusion criteria to determine eligibility.
Inclusion criteria are as follows: prevalence of ADHD (or any of the previous definitions of
ADHD including hyperactivity or ADD), included the analysis of Canadian data, and included
children or youth in the sample. Papers were excluded if they were examining ADHD in adults,
included data of non-Canadian populations, included qualitative data, or described methodology.
After applying these exclusions, six studies were identified. Reference lists of these studies were
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hand-searched which revealed another study meeting the inclusion criteria (Hauck et al., 2017).
All other papers were rejected because they described methodology, and/or did not analyze
Canadian data, and/or the target population was adults. Results were assessed by summarizing
objectives, population, definition of ADHD, method of measuring ADHD, estimates of ADHD,
and estimates by sex. After, results were organized by synthesizing studies based on whether
symptom checklists or actual ADHD diagnoses (either through survey indication or
administrative medical claims) were used.
Seven studies that have examined the prevalence of ADHD or ADHD symptoms (age range 1 to
24 years) in Canada are available (Brault & Lacourse, 2012; Brownell & Yogendran, 2001;
Georgiades et al., 2019; Hauck et al., 2017; McMartin et al., 2014; Szatmari et al., 1989;
Vasiliadis et al., 2017). Of the seven studies that have been reviewed, general prevalence
estimates have ranged from 1.5% (Brownell & Yogendran, 2001) to 10.49% (Georgiades et al.,
2019). The differences in prevalence of ADHD may be attributed to time of data collection
(which is impacted by the change of definition deemed by DSM criteria), age range of subjects
included in each study, self-report vs. objective measures, and differences in measures (survey
(includes use of symptom checklists based on DSM criteria or indication from parent of
diagnosis from a clinician) or assessment of administrative medical claims for actual ADHD
diagnoses). Prevalence studies examining ADHD symptoms have used symptom checklists,
typically based on DSM criteria to be filled out by parents, teachers and/or children/youth
(Georgiades et al., 2019; McMartin et al., 2014; Szatmari et al., 1989). Whereas prevalence
studies examining ADHD have required an indication from parents that their child was
diagnosed with ADHD by a clinician (Brault & Lacourse, 2012) or assessed administrative
medical claims for actual ADHD diagnoses and/or prescriptions with population denominators of
age appropriate regional populations (Brownell et al., 2011; Hauck et al., 2017; Vasiliadis et al.,
2017). Of the three studies that used symptom checklists (Georgiades et al., 2019; McMartin et
al., 2014; Szatmari et al., 1989), only two produced actual prevalence of ADHD symptoms
stratified by sex (Georgiades et al., 2019; Szatmari et al., 1989) while the remaining recorded
time trends. When comparing prevalence estimates by sex, Szatmari et al. (1989) produced the
largest prevalence of ADHD symptoms estimate for males compared to the other studies that
used actual ADHD diagnoses and Georgiades et al. (2019) produced the largest prevalence of
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ADHD symptoms estimate for females compared to other studies that used actual ADHD
diagnoses.
The following three studies utilized prevalence statistics based on symptom checklists; all were
from the Ontario Child Health Study (OCHS) except the study by McMartin et al. (2014), where
scales were adapted from the OCHS. McMartin et al. (2014) investigated trends in prevalence of
symptoms of ADHD based on hyperactivity scores from 1994/95 through to 2008/09 in Canada.
They examined data from Statistics Canada’s, National Longitudinal Survey of Children and
Youth (NLSCY), which is a longitudinal study of Canadian youth that follows their development
and well-being from birth to early adulthood. McMartin et al. (2014) utilized NLSCY data from
those aged 10 years or older. The sample size included of 11,725 participants. The case
definition of ADHD symptoms was based on hyperactivity scores to identify youth who would
likely qualify for psychiatric diagnosis from symptom criteria based on the DSM-III. This scale
was adapted from questionnaires used in the Montreal Longitudinal Survey and the OCHS.
Questionnaires were completed on paper at home or in a private setting and hyperactivity
symptoms were self-reported. McMartin et al. (2014) found that the mean hyperactivity score
significantly increased over time in participants aged 10-11 years (change per 2-year cycle, 0.16,
95% confidence interval [CI] [0.02-0.12]), participants aged 12-13 years (0.13, 95% CI [0.090.18]), but not among those aged 14-15 years (0.04, 95% CI [-0.01-0.09]). Unfortunately,
specific rates were not reported, only change in mean score were reported. No sex specific
prevalence estimates were recorded.
Szatmari et al. (1989) examined ADD with hyperactivity symptoms (known as “ADDH”
symptoms) and “ADD” based on a symptom checklist from the OCHS. Szatmari and colleagues
(1989) studied the six-month prevalence for symptoms of the historical diagnosis of “ADDH”, in
Ontario children and youth (4 to 16 years of age). This was an interviewer-administered
population-based survey of 2,052 households with eligible children or youth (whose usual place
of residence was a household dwelling in Ontario); 91% (n = 1869) participated in the survey.
Problem checklists based on DSM-III criteria for ADD with and without hyperactivity were
completed by parents, teachers and also youth 12-16 years of age to measure “ADDH” and
ADD, although such checklists did not provide thresholds for approximating individual
psychiatric disorders (Boyle, et al., 2019). The findings indicated that the prevalence of “ADDH”
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symptoms was 9.4% for males age 4-11 and 2.9% for males age 12-16, while prevalence was
2.8% for females age 4-11 and 1.4% for females age 12-16. However, for ADD, prevalence was
1.4% for males age 4-11 and 1.4% for males age 12-16, while prevalence was 1.3% for females
age 4-11 and 1.0% for females age 12-16, indicating a much higher prevalence of hyperactivity
symptoms for males than females (Szatmari et al., 1989).
Another paper used the 2014 data by OCHS (Georgiades et al., 2019). The 2014 OCHS assessed
families with children and youth aged 4 to 17 years (n = 6,537). The survey design included area
and household stratification by income and a 3-stage cluster sampling of areas and households in
order to yield a probability sample of families (Boyle et al., 2019). The OCHS assessed common
mental symptoms (including ADHD symptoms) occurring in the past 6 months based on the
DSM-IV (text revision) using the modified version of the Mini International Neuropsychiatric
Interview for Children and Adolescents (MINI-KID) (Georgiades et al., 2019). The parent report
of ADHD symptoms in children and youth (4-11 years) was 10.49% (14.77% in males and
6.00% in females). The parent report of ADHD symptoms in youth (12-17 years) was 5.19%
(7.51% in males and 2.73% in females), whereas the youth report of ADHD symptoms in youth
(12-17 years) was 6.19% (7.78% in males and 4.53% in females). It is important to note that
parents reported higher ADHD symptoms in males compared to self-reported symptoms, while,
parents reported lower ADHD symptoms in females compared to self-reported symptoms.
One Canadian population-based study examined actual ADHD diagnoses through a self-report
survey that asked parents for an indication of diagnosis of ADHD by a clinician (Brault &
Lacourse, 2012). Brault and Lacourse (2012) compared trends in prevalence of ADHD diagnosis
between 1994 and 2007 of Canadian preschoolers and school-aged children (specifically,
children aged 3-9 years). Brault and Lacourse (2012) used the same data (NLSCY) as McMartin
et al. (2014) but had different objectives; McMartin et al. (2014) sought to investigate trends in
the prevalence of ADHD symptoms whereas Brault and Lacourse (2012) reported actual
prevalence estimates of ADHD. Brault and Lacourse (2012) compared data of three crosssectional samples (n = 12,595 (1994/95), n = 13,904 (2000/01), and n = 14,655 (2006/07)) of
non-referred children from the NLSCY. ADHD diagnosis was reported by each child’s parent or
guardian. The prevalence of ADHD was 1.7% in 2000/01 and 2.6% in 2006/07. From 2000 to
2007, the prevalence of ADHD increased by 1.5-fold (Brault & Lacourse, 2012). Males’
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prevalence for ADHD was higher than that of females’ prevalence for ADHD, but females
showed a steeper increase over time. Males’ prevalence for ADHD was 2.6% in 2000/01 and
3.7% in 2006/07. Females’ prevalence for ADHD was 0.9% in 2000/01, and 1.5% in 2006/07.
Information regarding ADHD diagnosis is limited to the 2000s, as this information was not
collected in 1994/95.
Three Canadian population-based studies examined actual ADHD diagnoses by assessing
administrative medical claims for ADHD diagnoses and/or prescriptions with population
denominators of age appropriate regional populations (Brownell et al., 2001; Hauck et al., 2017;
Vasiliadis et al., 2017). Brownell and Yogendran (2001) examined physicians’ diagnosis rates
for ADHD for 4,787 children and youth (up to the age of 19 years) in the province of Manitoba
in 1995/96. In 1999, the prevalence of childhood ADHD was 1.5% and the diagnoses were made
primarily by paediatricians (47%) and general practitioners (36%) followed by psychiatrists
(17%) in 1999. In 2011/12, diagnoses were made primarily by general practitioners (52%),
followed by psychiatrists (24%), and paediatricians (23%). There were higher prevalence
estimates reported for males (2.4%) than for females (0.6%). Hauck et al. (2017) assessed the
prevalence and characteristics of children and youth (n = 29, 256) aged 1-24 years, with ADHD
in Ontario. Definite cases of ADHD were defined by family physician recording a diagnosis of
ADHD. The prevalence of ADHD was 5.4%; prevalence of ADHD among males was 7.9% and
2.7% among females. Vasiliadis et al. (2017) aimed to evaluate trends and to assess and report
over a decade of prevalence of children and youth (1-17 and 18-24) in outpatient and inpatient
settings with diagnosed ADHD in Canada (provinces included Manitoba, Ontario, Quebec, and
Nova Scotia). The prevalence of ADHD for those between 1-17 years of age increased from
1999 to 2011/2012 for all provinces. For Ontario specifically, the prevalence of ADHD for those
between 1-17 years of age increased from 1.06% to 1.10%. The prevalence of ADHD for those
18-24 years of age (0.15% in 1999; 0.53% in 2011/12) was lower than the prevalence of ADHD
for those 1-17 years of age. When stratified by sex, prevalence estimates were significantly
higher in males than in females in the four provinces in 1999 to 2011. The age-standardized
prevalence of ADHD by sex in 1999/2000 in Ontario was 1.65 for males and 0.45 for females.
The age-standardized prevalence of ADHD by sex in 2011/12 in Ontario was 1.60% for males
and 0.58% for females. Although males consistently have higher ADHD prevalence than
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females, the gap in ADHD diagnosis between males and females has been getting smaller
(Vasiliadis et al., 2017).
To sum, a number of studies on prevalence of ADHD and ADHD symptoms have been
conducted in Canada. These studies have found variation with the prevalence estimates from
1.5% (Brownell & Yogendran, 2001) to 6.2% (Georgiades et al., 2019), a range from 2.4%
(Brownell & Yogendran, 2001) to 14.77% (Georgiades et al., 2019) for males, and a range from
0.6% (Brownell & Yogendran, 2001) to 6% (Georgiades et al., 2019) for females. These
variations with ADHD estimates may be due to differences in measures (survey (includes use of
symptom checklists based on DSM criteria or indication from parent of diagnosis from a
clinician) or assessment of administrative medical claims for actual ADHD diagnoses), selfreport vs. objective measures, who provided the information (clinician, parent, teacher, or youth),
time of data collection (which is impacted by the change of definition deemed by DSM criteria),
and sociodemographic information (age) of the children and youth being assessed for ADHD
(Skounti et al., 2007). Studies measuring prevalence of ADHD symptoms have used checklists of
symptoms (McMartin et al., 2014; Szatmari et al., 1989) whereas studies measuring prevalence
of ADHD have used clinical diagnoses through surveys asking for parents to indicate diagnosis
of child or youth from a clinician (Brault & Lacourse, 2012) or administrative medical claims
(Brownell et al., 2001; Hauck et al., 2017; Vasiliadis et al., 2017). Symptom checklists are
generally based on DSM criteria that typically measure the symptoms of a disorder, but without
the professional diagnosis and breadth and depth of evidence needed for a formal diagnosis. The
symptom checklists can be a lengthy scale or a short screener. Clinical diagnosis by a physician
or psychologist is based on DSM criteria that include behavioural or psychological syndromes
that occur in an individual. The underlying psychobiological dysfunctions reflected by these
syndromes result in functional impairments that “reduce the quality of social, academic or
occupational functioning” (Diagnostic and Statistical Manual of Mental Disorders, 2014). These
data can be collected from clinical assessments, medical charts or electronic databases or based
on parents’ reports of their child having received a diagnosis and/or prescription for an ADHD
medication. These different approaches to measure ADHD prevalence and different data
collection designs can affect prevalence estimates across these studies. Based on the studies
summarized in this section, the lower prevalence estimates came from actual diagnoses from a
study that used administrative medical records (Brownell & Yogendran, 2001) and the higher
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prevalence estimates came from a study using a symptom checklist (Georgiades et al., 2019;
Szatmari et al., 1989). It is possible that studies that used a symptom checklist to measure ADHD
produced larger prevalence statistics compared to studies that used administrative medical
records because symptom checklists are possibly more inclusive (could be capturing broader
spectrum of psychological symptoms but not actually reflecting a true disorder), whereas
diagnoses based on DSM criteria by physicians or psychologists are more exclusive (as these
ADHD symptoms must not be better explained by another mental disorder such as a mood
disorder).
On the other hand, not all children and youth with ADHD have been diagnosed, so relying only
on diagnoses could provide a lower prevalence. Hence, one strength of utilizing symptom
checklists is that they capture children and youth with ADHD who have not been diagnosed.
Therefore, it is a tradeoff, in particular, as mentioned before; females tend to exhibit less
disruptive behaviours so they are less likely to be pushed by schools to be assessed. This leads to
fewer females being seen by health care professionals which results in a smaller number who
actually receive a diagnosis of ADHD.

2.3 International Prevalence Estimates of ADHD and ADHD
Symptoms
A number of international papers are available on the prevalence of ADHD and ADHD
symptoms in children and youth (age range of 19 and under) (Catalá-López et al., 2012; Green et
al., 2019; Madruga et al., 2012; Polanczyk et al., 2010; Polanczyk, Willcutt, Salum, Kieling, &
Rohde, 2014; Polanczyk, Salum, Sugaya, Caye, & Rohde, 2015; Reale & Bonati, 2018; Sonnby
et al., 2011; Thomas, Sanders, Doust, Beller, & Glasziou, 2015; Wang et al., 2017; Xu,
Strathearn, Liu, Yang, & Bao, 2018). International studies, compared to Canadian studies,
however, have found larger variation in ADHD/ADHD symptoms prevalence rates among
children and youth from 3.4% (Polanczyk et al., 2015) to 20.90% (Sonnby et al., 2011).
International studies that reported sex differences generally indicated higher prevalence of
ADHD in males than in females (Catalá-López et al., 2012; Reale & Bonati, 2018) although
some studies have reported higher prevalence of ADHD symptoms in females than in males
(Gritti et al., 2014; Madruga et al., 2012; Polanczyk et al., 2010; Sonnby et al., 2011).
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International studies that have used diagnostic measures of ADHD (Polanczyk et al., 2014;
Polanczyk et al., 2015; Xu et al., 2018) have similar prevalence rates overall, including for males
and females compared to Canadian studies. In a meta-analysis of 135 studies, Polanczyk et al.
(2014) reviewed research using original surveys published between 1978 and 2006 from across
the world (i.e., North America, Europe, Asia). The meta-analysis assessed community and school
samples of children and youth (18 years of age or under) to generate a point prevalence statistic,
with diagnoses of ADHD based on the DSM (III, III-R, or IV). The percentage of children and
youth (18 years of age or younger) with a diagnosis of ADHD increased between 2003 and 2007
from 7.8% to 9.5%; however, no separate prevalence estimates for males and females were
provided (Polanczyk et al., 2014).
A year later, Polanczyk et al. (2015) conducted another systematic review for prevalence studies
of mental disorders investigating probabilistic community samples of children and youth with
standardized assessment methods that derived diagnoses according to the DSM or ICD. Papers
were selected based on consensus if they satisfied the following criteria: 1) original prevalence
studies assessing community samples; 2) probabilistic sampling strategy; 3) use of a standardized
assessment procedure deriving diagnosis according to DSM-III, DSM-III-R, DSM-IV, ICD-9, or
ICD-10; and 4) inclusion of children and youth up to age 18. Forty-one studies conducted in 27
countries from every world region were included (North America, Europe, Asia, Africa, South
America and the Caribbean, Middle East, and Oceania). Studies meeting inclusion criteria were
published from 1985 to 2012. Informants included: 1) parent, child, and teacher; 2) parent and
teacher; 3) parent and child; 4) parent; or 5) child. The worldwide-pooled prevalence of ADHD
was 3.4%; however, no separate prevalence estimates for males and females were provided.
Lastly, in the United States, according to analysis of data collected by the National Health
Interview Survey, the prevalence rates of diagnosed ADHD among children and youth (age 4-17)
in the past twenty years has progressively increased from 6.1% in 1997/1998 to 10.2% in
2015/2016 (Xu et al., 2018).
Other international studies have used symptom checklists; these studies have found much higher
prevalence rates of ADHD symptoms than Canadian studies that used symptom checklists
(Green et al., 2019; Madruga et al., 2012; Sonnby et al., 2011). Furthermore, no Canadian studies
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presented higher prevalence of ADHD symptoms among females than males; however, most of
these international studies that used symptom checklists have found higher prevalence rates of
ADHD symptoms in females rather than in males (Madruga et al., 2012; Polanczyk et al., 2010;
Sonnby et al., 2011). For example, Madruga et al. (2012) used the Brazilian National Alcohol
Survey to select 3,007 participants aged 14-19 years old (males = 49.7%). The questionnaire
used was the Brazilian adaptation of the Hispanic Americans Base Line Alcohol Survey
questionnaire. ADHD symptoms were assessed using the reduced version of the commonly used
Adult ADHD Self-Report Scale (ASRS-v1.1) Screener adapted to the Portuguese language using
the score 4 as the cutoff point. Nearly one out of ten adolescents recorded ADHD symptoms
(9.7%) and females were significantly more likely to meet criteria for ADHD than were males
(13.02% and 8.75% respectively).
Sonnby et al. (2011) examined the Survey of Adolescent Life in Vestmanland 2006 data in
Sweden of all secondary school students (age 15-18 years old). A total of 4,910 participants
(male = 50.37%; overall response rate of 80.3%) were in this study. ADHD symptoms were
measured using the ASRS Screener. Of this sample, a total of 20.90% reported ADHD
symptoms. Interestingly, 18.4% of males reported ADHD symptoms and 23.5% of females
reported ADHD symptoms.
Polanczyk et al. (2010) assessed a representative household sample of the Brazilian population
for symptoms of ADHD with the ASRS Screener (Brazilian-Portuguese version) using the first
Brazilian National Alcohol Survey in 2005-2006 (survey response rate = 66.4%). The sample
was weighted to correct for the probability of selection of responses into the sample and nonresponse rates. The sample was comprised by 3,007 participants, with an overall prevalence of
symptoms of ADHD of 5.8%. The prevalence of symptoms of ADHD by age range was 7.6%
(14-17 years of age), 5.2% (18-44 years of age), and 6.1% (45+ years of age). Females presented
a higher prevalence for ADHD symptoms than males (Odds Ratio (OR) = 2.03, 95% CI [1.33.2]. Among those 18-44 years of age, females had a higher prevalence of ADHD symptoms
than males (OR = 2.04, 95% CI [1.0-4.1]).
Green et al. (2019) administered a short symptom checklist (ASRS Screener) in an adolescent
community sample in the US. Two school districts with state test passage rates substantially

14

higher than state or national averages (approximately 90%) administered anonymous
assessments of mental health and school functioning. Middle and high school students (grades 612; ages 11-18 years old) for a total of 2,472 students (46.6% male; 94% white) completed the
assessments (response rate = 94.4%). The overall prevalence of ADHD symptoms was 14.6%.
Males reported slightly higher scores than females, although this difference was not significant.
The ASRS-v1.1 Screener scores increased significantly with age (from a mean of 5.4 among 6th
graders to 9.6 among 11th graders, p < .001); similarly, where 9.6% of middle school students
reported symptoms of ADHD, 19.6% of high school students reported symptoms of ADHD.
12.5% of those in grade 9 reported symptoms of ADHD, 17.1% of those in grade 10 reported
symptoms of ADHD, 26.0% of those in grade 11 reported symptoms of ADHD, and 23.5% of
those in grade 12 reported symptoms of ADHD.
To sum, a number of studies on prevalence of ADHD have been conducted internationally.
These studies have found wider variation with the estimates compared to Canadian studies.
However, international studies that used diagnostic measures of ADHD have similar prevalence
rates overall and for males and females compared to Canadian studies. Some international
studies that have used symptom checklists have found much higher prevalence rates of ADHD
symptoms than Canadian studies that used symptom checklists (Green et al., 2019; Madruga et
al., 2012; Sonnby et al., 2011) and in particular significantly higher prevalence rates of ADHD
symptoms in females rather than in males (Madruga et al., 2012; Polanczyk et al., 2010; Sonnby
et al., 2011). These variations with ADHD estimates may be due to differences in measurement
style (i.e., self-report compared to objective measures, who provided the information) or time of
data collection and sociodemographic information of the children and youth being assessed for
ADHD (Skounti et al., 2007). These different approaches to measure ADHD or ADHD
symptoms prevalence and different data collection methods can influence prevalence estimates
across these studies. Similar to Canadian studies, all international studies that reported an overall
prevalence estimate based on symptom checklists showed higher estimates than prevalence
statistics based on actual DSM diagnosis.

2.4 ADHD and Sex
Research shows that ADHD is a disorder of polygenic inheritance with symptoms of
hyperactivity and impulsivity predominantly more apparent in males with ADHD than in females
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with ADHD (Wang et al., 2017). Disruptive behaviours, such as aggression, disciplinary
violations, and other behaviours violating social norms (which are easily observed by parents and
teachers) may be a reason why males with ADHD are more likely to be identified than females
with ADHD (Wang et al., 2017). Conversely, females with ADHD are less likely to have
disruptive behaviour disorders and are more likely to report higher prevalence of symptoms of
inattention, which are more covert than those of hyperactivity and impulsivity (Biederman &
Faraone, 2004). Although females are more likely to have the primarily inattentive subtype of
ADHD, its consequences are less often studied (Elkins, et al., 2018). Gaub and Carlson (1997)
suggested in their meta-analysis that differences in the phenotypic expression of the disorder
may be driving diagnostic referrals of more males than females. However, Vasiliadis et al.
(2017) believes that the gap in ADHD diagnosis between males and females is getting smaller
and may reflect increased identification of ADHD in females, who more often exhibit symptoms
of inattention, which may be more difficult to detect than hyperactivity. For example, Brault and
Lacourse (2012) reported that the steepest increase over time in ADHD occurred in females and
this trend could reflect either the greater attention females are now receiving or the
acknowledgment that sex differences may result from referral bias. Furthermore, several
international studies have reported higher ADHD symptoms among females than males (Gritti et
al., 2014; Madruga et al., 2012; Polanczyk et al., 2010; Sonnby et al., 2011).
Most studies regarding ADHD use clinical samples. Prior clinical studies of sex and ADHD are
limited by small sample sizes (Rooney, Chronis-Tuscano, & Yoon, 2011; Egan, Dawson, &
Wymbs, 2017), impeding an adequate understanding of sex differences. It is imperative that
future studies have large enough sample size to examine sex differences, as the greater the
sample size, the greater the power of the test, and there have been instances where there was
insufficient power to examine sex differences (Rooney et al., 2011; Egan et al., 2017). Prior
clinical studies of sex and ADHD are also limited by the absence of gender matched
comparisons. One of the reasons for this limitation is because many clinical studies contain all
male samples which limits the ability to make inferences to females (Szatmari et al., 1989).
Although there are ADHD studies by sex (Brault & Lacourse, 2012; Brownell & Yogendran,
2001; Hauck et al., 2017; Szatmari et al., 1989; Vasiliadis et al., 2017), there are also ADHD
studies that did not record sex specific prevalence statistics (Polanczyk et al., 2014; Polanczyk et
al., 2015). Hence, despite the importance of examining sex differences, not all studies that have
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examined ADHD have further analyzed sex differences, or if they have, many did not record
results specific to males and females (Polanczyk et al., 2014; Polanczyk et al., 2015; Thomas et
al., 2015). Therefore, there is a need to understand sex differences related to ADHD for
Canadian youth.

2.5 ADHD Symptoms and Substance Use
There has been growing research showing that those with ADHD symptoms are at increased
risks of adverse outcomes (Fergusson et al., 2007). These outcomes span substance use (Flory et
al., 2003). Substance use refers to the ingestion of drugs of abuse, inhalants, or medications for
the intent of intoxication (APA, 1994). Substance use constitutes a substantial clinical, public
health, and economic concern (Demyttenaere et al., 2004). Youth with ADHD symptoms are
especially susceptible to engaging in substance use as they have difficulties with impulse control,
which increases susceptibility for developing addictive behaviour (Faregh & Derevensky, 2011).
Furthermore, substance use may share a common genetic vulnerability with ADHD because the
dopamine transporter gene (DAT1) and the dopamine receptor D4 gene (DRD4) have been
involved in the etiology of both ADHD (Todd et al., 2005) and substance use pathways
(Guindalini et al., 2006; Shao et al., 2006).
The majority of studies examining the relationship between ADHD symptoms and substance use
examined the commonly popular substances that children and youth use: alcohol (Elkins et al.,
2018; Fergusson et al., 2007; Flory et al., 2003; Galéra et al., 2008; Sihvola et al., 2011;
Upadhyaya & Carpenter, 2008), tobacco cigarettes (Fergusson et al., 2007; Flory et al., 2003;
Galéra et al., 2005; Galéra, 2013; Kollins et al., 2005; Sihvola et al., 2011; Upadhyaya &
Carpenter, 2008) and cannabis (Elkins et al., 2018; Fergusson et al., 2007; Flory et al., 2003;
Galéra et al., 2008; Upadhyaya & Carpenter, 2008). One has examined cocaine (Galéra et al.,
2013) and no studies using youth samples have examined the increased risk of crack-cocaine,
methamphetamine, or ecstasy among those with ADHD symptoms.
Examining substance use categories separately is important because there is evidence of different
patterns of use; for example, alcohol and cannabis use may differ from tobacco cigarette use
because the former two are depressants and the latter is a stimulant. There is evidence that the
rate of substance use for those with ADHD was significantly higher for tobacco use and cocaine
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use than for alcohol use or cannabis use (Lambert & Hartsough, 1998). Furthermore, it is posited
that people with ADHD symptoms are more likely to use stimulants than depressants because
stimulants share chemical and mechanistic similarities to methylphenidate, a common ADHD
medication (Arnsten, 2006).

2.5.1 Alcohol
Alcohol is the most commonly used substance among children and youth (Barnes, Welte,
Hoffman, & Tidwell, 2009; Johnston, O’Malley, Bachman, & Schulenberg, 2007) and remains
the substance with the highest prevalence of use by Canadian students in grades 7 through 12
(Government of Canada, 2019). The prevalence of use of alcohol in the past 12 months by
students (grades 7-12) was 44%, and remains unchanged from 2016-2017 (Government of
Canada, 2019). Youth who are influenced by older people of legal age are more likely to use
alcohol (Mezzich et al., 1999). When students were asked how difficult they thought it would be
to obtain alcohol if they desired, 66% responded that they thought it would be “fairly easy” or
“very easy” (Government of Canada, 2019). Identification of vulnerable subgroups of the
population has been an important research agenda in the effort to understand risk and to develop
targeted interventions. Given that alcohol use lies along the continuum of externalizing
psychopathology (Krueger, Markon, Patrick, & Iacono, 2005; Markon & Krueger, 2005), it may
be associated with other externalizing symptomatology (such as ADHD symptoms). However,
results from literature indicates conflicting results with the relationship between ADHD and
alcohol use.
Some of the research examining the relationship between ADHD symptoms and alcohol use
indicates that children and youth with ADHD symptoms are not more likely to use alcohol than
children and youth without ADHD symptoms (Flory et al., 2003; Galéra et al., 2008; Upadhyaya
& Carpenter, 2008). Flory et al. (2003) examined the relationship between ADHD symptoms and
other childhood disruptive behaviours with substance use in young adulthood as part of a 10-12
year longitudinal examination of substance use and psychopathology. Youth (n = 481; male =
50.1%) from multiple schools from a midwestern metropolitan area in the United States were
assessed by means of a written questionnaire in the 1987-1988 school year before they started 6th
grade. Follow up data were collected from participants over a 5-year period from 6th-10th grade.
Participants completed questionnaires on at least three of these five occasions and took part in a
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mailed survey at age 19-21. After, participants were contacted by telephone and participated in a
3-4 hour laboratory study. Childhood ADHD symptoms were assessed retrospectively during
laboratory protocol using an 18-item questionnaire with items corresponding to APA DSM-IV
criteria for ADHD (APA, 1994). Past-month reporting of alcohol use was taken from the mailed
survey. Bivariate correlation revealed that ADHD symptoms were not significantly related to
alcohol use (r = -.01, p = NS). However, CD symptoms, that measured delinquent behaviours,
were significantly related to alcohol use (r = .17, p < .01). In the regression analysis for alcohol
use, CD symptoms made a significant and unique contribution, beyond that of ADHD
symptoms; however, ADHD symptoms (OR = 0.92) did not make a significant and unique
contribution beyond that of CD symptoms for alcohol use. It is important to note that researchers
used a significance level of p < .01 to minimize the possibility of Type I error. ADHD
symptomology was unrelated to sex of participants.
Galéra et al. (2008) examined ADHD symptoms in childhood and alcohol use in adolescence
among the youth gazel cohort (an open and general-purpose epidemiological laboratory that
examines the long-term follow-up of a cohort). Participants included 916 children and youth
(males = 45.96%) aged 7 to 18 and data were extracted from 1991 to 1999. Youth and the
parents or guardians of the children/youth were given questionnaires. ADHD symptoms were
measured in 1991 with the 11-item Child Behavior Checklist (CBCL) (a validated and widely
used tool in clinical and epidemiological studies) scale for attention problems. An example of
some of the symptoms include: “acts young”, “can not concentrate”, “can not sit still”,
“daydreams”, “impulsive”, “stares blankly”; CBCL was also used to measure covariates
(anxious/depressed, CD symptoms, etc.). The youth questionnaire asked detailed questions about
substance use (adapted from the Monitoring the Future (MTF) study). For alcohol use, two
variables were created: 1) a binge drinking variable (had five or more drinks in a row at least
twice in the last two weeks versus had five or more drinks in a row at most once versus did not
have five or more drinks in a row in the last two weeks); and 2) a regular drinking variable (has
drunk at least 10 times during the last 30 days versus has drunk less than 10 times or has not
drunk during the last 30 days). ADHD symptoms were not significant in the bivariate analysis
with alcohol binge drinking or for regular drinking. ADHD symptoms had an OR of 0.73 (95%
CI [0.29-1.85]) for binge drinking and an OR of 0.80 (95% CI [0.36-1.78]) for regular drinking.
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Irrespective of binge or regular drinking, no association was found between alcohol use and
ADHD symptoms in the bivariate analysis or multivariate modelling of the data, for both males
and females. CD symptoms were not significantly related to alcohol use for males and females.
In females, the environmental risk factor of low SES was predictive of regular alcohol use.
Upadhyaya and Carpenter (2008) aimed to understand the relationship between ADHD
symptoms and past-year alcohol use in a convenience sample (n = 334; response rate of 56%;
mean 20.6 years; male = 39%) of college students in the states. Past year alcohol use was
measured ordinally (i.e., once per year, six times per year, once per month, twice per month,
once per week, three times per week, five times per week, every day). The Current Symptom
Scale-Self Report is a rating scale and was used for the assessment of ADHD symptoms in the
past six months by subscales (nine items each). Each item was scored from 0-3 (never/rarely,
sometimes, often, or very often) and was counted as a symptom of ADHD only if endorsed as
often or very often. All analyses controlled for both lifetime CD symptoms and antisocial
personality disorder (ASPD) symptoms, with both entered as covariates in the regression model;
however, the influence of these covariates in the relationship between ADHD symptoms and
alcohol use was never discussed. The number of ADHD symptoms was not significantly related
to past year alcohol use (OR = 1.1; 95% CI [0.98–1.16]). ADHD symptomatology was unrelated
to sex.
Other studies suggest that there is a relationship between ADHD symptoms and alcohol use
among youth (Elkins et al., 2018; Fergusson et al., 2007; Sihvola et al., 2011), specifically that
risk of alcohol use may be more apparent in females with ADHD symptoms (Elkins et al., 2018;
Sihvola et al., 2011) and ADHD symptoms decrease the risk of alcohol use (Fergusson et al.,
2007). It is important to note that these are contradictory findings. Elkins and colleagues (2018)
used population-based twin samples recruited for the Minnesota Twin Family Study (n = 3762
individual twins; male = 48%) to examine if childhood inattentive or hyperactive-impulsive
symptoms predicted alcohol use by age 17. Primary caregiver reports of twins, including lifetime
ADHD symptoms (consistent with DSM-5) and CD symptoms at baseline were obtained with
the Diagnostic Interview for Children and Adolescents-Revised (Elkins et al., 2018). Frequency
of use was coded to reflect typical escalation during adolescence; for alcohol frequency: 0 =
never, 1 = less than once a month, 2 = once a month/nearly weekly, 3 = weekly/daily. Overall
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effects were adjusted for covariates (age, parental SES, and sex). When co-occurring use of other
substances and conduct/oppositional defiant symptoms were considered, hyperactivityimpulsivity remained significantly associated to alcohol use (p < .05), but inattention became
non-significant. When sex differences were significant, ORs were presented separately. ADHD
symptoms, specifically inattentive symptoms were significantly related to weekly/daily drinking
(OR = 1.08 (95% CI [1.03-1.13]), p < .001) and maximum number of drinks in 24 hours (OR =
1.07, p < .001). ADHD symptoms, specifically hyperactivity-impulsivity symptoms were
significantly related to weekly/daily drinking (OR = 1.20 (95% CI [1.14-1.27]), p < .001) and
maximum number of drinks in 24 hours (OR = 1.16, p < .001) in females significantly more than
maximum number of drinks in 24 hours for males (OR = 1.08, p < .001). The risk of alcohol use
was more apparent in females (Elkins et al., 2018); reasons for this could be that females
experience greater social and academic consequences than males (Elkins, Malone, Keyes,
Iacono, & McGue, 2011) leading them to use alcohol as a way to cope with these consequences.
Sihvola and colleagues (2011) aimed to examine the relationship between ADHD symptoms and
alcohol use. They conducted a population-based study in Finland (n = 1545; 83% completion
rate; males = 51%; age 14-17) and assessed for DSM-IV based ADHD symptoms using the
Multidimensional Peer Nomination inventory. Assessment for ADHD symptoms included four
inattentive symptoms and seven hyperactivity-impulsivity symptoms; sum scores of each
symptom were constructed as the mean of the items. ADHD symptoms were reported by parents
and teachers; however, data reported between the two groups were similar. Alcohol use was
reported by youth and was measured as frequent use (daily or a couple of times a week), once a
week, couple times a month, once a month, once a couple of months, 2-4 times a year, once a
year or more rarely, or no use. By the age of 17.5 years, 15.4% of females exhibiting high
inattentiveness reported weekly alcohol use while 8.8% of males exhibiting high inattentiveness
reported weekly alcohol use. Young females with core symptoms of ADHD, such as
inattentiveness, may be at higher risk of substance use than young males. Larger effects of
ADHD symptoms on alcohol consumption in females were found, consistent with Elkins et al.
(2018). Alcohol use was not entered as a main interest variable in the multinomial logistical
regression but rather it was controlled for when examining tobacco cigarette use.
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Fergusson et al. (2007) used data gathered during the Christchurch Health and Development
Study, which is a longitudinal study of 1,265 children (~50% male) born in the Christchurch
(New Zealand) urban region during a 4-month period in mid-1977. This cohort has been studied
at birth and at annual intervals to age 16 years, 18, 21, and 25 years. Data have been gathered
from parental interviews, self-reports, psychometric tests, teacher reports, medical and other
official records. The child’s tendencies to ADHD symptoms were recorded from parent and
teacher questionnaires at the ages 7-9. All items were scored on a three-point scale from “not at
all” to “a great deal”. These measures were then averaged over the 3-year period to provide an
overall scale score ranking. Parents and teenagers were questioned in separate interviews on
measures of ADHD symptoms based on the Revised Behaviour Problems Checklist at the ages
of 14-16. Parent and self-report assessments were combined to classify the individual as having
ADHD symptoms if s/he met DSM-III-R diagnostic criteria on the basis of either parental or
self-report over the interval from 14–16 years. At age 18, 21, and 25, participants were asked
about alcohol use. At each assessment participants were questioned about their use of alcohol in
the previous 12 months, including the frequency of alcohol consumption and the amounts
consumed. Participants recorded the use of alcohol if they consumed any alcoholic drink in the
preceding 12 months. Family SES and CD symptoms were covariates controlled for in the
following analyses. Increasing ADHD symptoms in middle childhood were associated with
decreasing rates of alcohol use and rates of use tended to decline significantly with increasing
ADHD symptoms. Early CD symptoms and ADHD symptoms proved to be correlated (r = .68; p
< .0001). Alcohol use was unrelated to early CD symptoms and negatively related to ADHD
symptoms. Risk Ratio (RR) or OR were not produced. No sex differences were discussed.
Researchers assessed based on rates of alcohol use by symptoms (1 low, 2 symptoms, 3
symptoms, 4 symptoms, and 5 high symptoms). The report indicates that rates of use decline
significantly with increasing ADHD symptoms.
In summary, some studies did not find any relationship between ADHD symptoms and alcohol
use for both frequency of alcohol use (e.g., past month of alcohol use, past year use) (Flory et al.,
2003; Upadhyaya & Carpenter, 2008) and binge drinking (e.g., five or more drinks in a row at
least twice a week in the last two weeks) (Galéra et al., 2008). Other studies suggest that there is
a relationship between ADHD symptoms and alcohol use among youth (Elkins et al., 2018;
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Fergusson et al., 2007; Sihvola et al., 2011). Some found that ADHD symptoms increases the
risk of alcohol use (Elkins et al., 2018; Sihvola et al., 2011) while others found that ADHD
symptoms decrease the rates of alcohol use (Fergusson et al., 2007). Furthermore, both Elkins et
al. (2018) and Sihvola et al. (2011) found larger effects of ADHD symptoms on alcohol in
females than in males. Elkins et al. (2018) found that ADHD symptoms (specifically
hyperactivity-impulsivity symptoms) were significantly related to alcohol use in females,
significantly more than in males. Sihvola et al. (2011) found that significantly more females
exhibiting high inattentiveness reported alcohol use compared to males exhibiting high
inattentiveness.

2.5.2 Tobacco Cigarettes
Tobacco cigarettes is one of the most commonly used substance by children and youth (Barnes et
al., 2009). In 2018/19, 19% of students in grades 7 through 12 had ever tried smoking a cigarette
(even just a puff) (Government of Canada, 2019). The majority (84%) of students who smoked
in the past 30 days obtained their tobacco cigarettes from social sources (rather than retail
sources) (Government of Canada, 2019). Social sources include friends and family. Tobacco
cigarette use could be used as self-medication among ADHD individuals since nicotine has been
shown to improve general attention, learning, and memory, and to have positive effects on
cognitive/behavioural inhibition in youth with ADHD (Levin, 1992; Potter & Newhouse, 2004).
Furthermore, tobacco cigarettes is hypothesized to modulate dopaminergic pathways possibly
implicated in the pathophysiology of ADHD (Swanson et al., 2000). The majority of studies
indicate that ADHD symptoms are significantly associated with tobacco cigarette use (Fergusson
et al., 2007; Flory et al., 2003; Galéra et al., 2013; Kollins et al., 2005; Sihvola et al., 2011;
Upadhyaya & Carpenter, 2008), although sex differences may exist. For example, a study found
a significant relationship between ADHD symptoms and daily tobacco cigarette use in females
but not in males (Galéra et al., 2005).

Fergusson et al. (2007) measured tobacco cigarette use at age 18, 21, and 25. Those who reported
smoking a cigarette at any time in the previous month were classified as using tobacco cigarettes.
Increasing ADHD symptoms in middle childhood were associated with increasing rates of
tobacco cigarette use. Early CD symptoms and ADHD symptoms proved to be correlated (r =
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.68; p < .0001). RR or OR were not produced. No sex differences were discussed. Researchers
assessed based on rates of tobacco cigarette use by ADHD symptoms (1 low, 2 symptoms, 3
symptoms, 4 symptoms, and 5 high symptoms). The report indicates that rates of use increased
significantly with increasing ADHD symptoms.
Flory et al. (2003), described previously, also examined the relationship between ADHD
symptoms and other childhood disruptive behaviours with tobacco cigarette use in young
adulthood. Researchers analyzed past-month reporting of tobacco cigarette use. Sex did not
influence results in the multiple regression analysis. In the regression analyses for tobacco
cigarette use, CD symptoms made a significant and unique contribution, beyond that of ADHD
symptoms. Likewise, ADHD symptoms made a significant and unique contribution beyond that
of CD symptoms for tobacco cigarette use (OR = 1.09). It is interesting to note that the only
substance to which ADHD symptoms were uniquely related after the inclusion of the ADHD-CD
symptoms interaction term was tobacco cigarettes. This finding is consistent with prior research
that has demonstrated that ADHD symptoms are related to tobacco use even after the overlap
between ADHD symptoms and CD symptoms are taken into account (e.g., Disney, Elkins,
McGue, & Iacono, 1999).
Galéra et al. (2013) assessed the link between ADHD symptoms and tobacco cigarette use in
1,103 French youth (male: 41.2%) followed from 1991 to 2009, using the same measures as
Galéra et al. (2008). In 2009, youth reported their past 12-month use of tobacco cigarettes. Past
12-month regular tobacco smoking was defined as greater than or equal to one cigarette per
day/less than one cigarette per day. After accounting for covariates (anxious/depressed
symptoms, CD symptoms, and SES), ADHD symptoms were significantly related to regular
tobacco smoking 18 years later. Those who scored high > 90th percentile for ADHD symptoms
had higher odds for using regular tobacco cigarettes (OR = 2.74 (95% CI [1.79-4.21]), p < .05
(adjusted for only age and sex) and OR = 2.19 (95% CI [1.31-3.68]), p < .05 (fully adjusted)).
There were no sex differences in this study (the tests for effect modification by sex were nonsignificant).

24

Kollins et al. (2005) studied 15,197 participants (male = 49.5%; average age = 21.94 years) from
wave III of the National Longitudinal Study of Adolescent Health (of adolescents followed from
1995 to 2002) to examine the relation between self-reported ADHD symptoms and the lifetime
likelihood of being a regular smoker (defined by having smoked at least 1 cigarette a day for 30
days) while controlling for CD symptoms and SES. Participants were asked to retrospectively
report ADHD symptoms (analysis included nine inattention symptoms and eight
hyperactive/impulsive symptoms) experienced between the ages of 5 and 12 years. A symptom
was considered present if it was experienced “often” or “very often” and the total number of
symptoms reported was used as a measure of ADHD symptoms severity to assess the relation
between symptoms and smoking outcomes. For descriptive and bivariate analyses, individuals
were classified into one of four groups based on the number of reported symptoms: 1) six or
more inattentive symptoms, fewer than six hyperactivity symptoms; 2) six or more hyperactivity
symptoms, fewer than six inattention symptoms; 3) six or more inattentive symptoms and six or
more hyperactivity impulsivity symptoms; and 4) fewer than six hyperactivity impulsivity
symptoms and fewer than six inattention symptoms. Reporting higher numbers of CD symptoms
and reporting six or more inattention and/or hyperactivity-impulsivity symptoms were all
significantly associated with higher likelihood of ever regular smoking. In the controlled model,
each reported inattention and hyperactivity-impulsivity symptom significantly increased the
likelihood of ever regular smoking (OR= 1.11; 95% CI [1.08-1.14] and OR, 1.16; 95% CI [1.131.19], respectively). The unadjusted model for likelihood of ever regular smoking was significant
for inattentive symptoms (OR = 1.14 (95% CI [1.11-1.17])) and significant for hyperactivityimpulsivity symptoms (OR = 1.20 (95% CI [1.17-1.23])). The addition of demographic variables
and CD symptoms resulted in decreased ORs for both hyperactivity-impulsivity and inattention
symptoms, though both remained significant. To assess ORs for more clinically relevant
variables, the same models mentioned earlier were calculated using symptom cut-off variables as
predictors. The odds of becoming a lifetime regular smoker were 1.23 and 2.13 times greater for
those individuals with six or more inattention and hyperactivity-impulsivity symptoms,
respectively. There were no sex differences found in this study (p = .67).
Sihvola and colleagues (2011) assessed ADHD symptoms of adolescents aged 14-17. Their aim
was to examine ADHD symptoms and its contribution in predicting tobacco cigarette use after
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controlling for CD symptoms with multinomial analyses; importantly, sex differences were
evaluated. Tobacco cigarette use was measured as daily smokers, occasional smokers (not daily
smoking but smoking either less than once a week or once a week or more often), and
experimenters (“I have experimented with tobacco cigarettes but I don’t smoke”). In this
prospective three-wave data, high inattentiveness, hyperactivity and impulsivity rated by parents
and teachers were of importance regarding daily smoking behaviour among both sexes at age 14
(on average, 24% of females v. 21% of males with high symptoms smoked daily) and at age 17.5
(44% of females v. 39% of males smoked daily). Controlling for CD symptoms, both teachers’
and parents’ ratings of ADHD symptoms consistently predicted daily smoking at ages 14 and
17.5 among males and females.
Model 1 was a multinomial logistic regression model to examine the unadjusted association with
the outcomes (Sihvola et al., 2011). Model 2 included potential confounding covariates of daily
smoking behaviour, illicit drug use, alcohol use, co-existing symptoms of psychiatric disorders,
and interaction terms with sex. Models were also fit separately for males and females. Sex
differences were further tested with likelihood ratio tests to confirm significance of the
differences between coefficients in models separately fit for males and females.
In the multinomial logistic regressions, all risk ratios were lower after controlling for the
covariates, but still strongly significant (Sihvola et al., 2011). Young females with core
symptoms of ADHD, such as inattentiveness and hyperactivity, may be at higher risk of tobacco
cigarette use than young males, because females’ risk may not be mediated by CD symptoms, a
strong predictor of substance use. For example, when adjusted for covariates, females with
inattentiveness symptoms had a 2.9, 95% CI [1.7-5.0], p < .001 increased risk of smoking at age
17 (relative to not smoking at age 17), compared to females without inattentiveness symptoms.
Males with inattentiveness symptoms had a 2.5, 95% CI [1.6-3.9], p < .001 increased risk of
smoking at age 17 (relative to not smoking at age 17), compared to males without inattentiveness
symptoms. For hyperactivity symptoms, when adjusted for covariates, females with
hyperactivity symptoms had a 4.2 95% CI [1.9-9.1], p < .001 increased risk of smoking at age 17
(relative to not smoking at age 17), compared to females without hyperactivity symptoms. Males
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with hyperactivity symptoms had a 4.1 95% CI [2.3-7.3], p < .001 increased risk of smoking at
age 17 (relative to not smoking at age 17), compared to males without hyperactivity symptoms.
Upadhyaya and Carpenter (2008) assessed frequency of use in the past year for tobacco cigarette.
The number of ADHD symptoms was significantly related to past year smoking (OR = 1.1; 95%
CI [1.03–1.18]). For every one symptom increase in ADHD, the odds of using tobacco 5+ times
per week increased by 10%. For every one symptom increase in both hyperactive and inattentive
behaviours, the odds of using tobacco 5+ times per week increased by at least 17% (OR = 1.17;
95% CI [1.03–1.33]) and 18% (OR = 1.18; 95% CI [1.06–1.33]), respectively. Upadhyaya and
Carpenter (2008) found that ADHD symptoms were linked to greater tobacco cigarette use even
after controlling for conduct problems and ADHD symptomatology was unrelated to sex.
Galéra et al. (2005), on the other hand, did not find a significant relationship between ADHD
symptoms and tobacco cigarette use for both sexes. Galéra et al. (2005) examined 916 children
and youth (males = 45.96%) aged 7 to 18 and data were extracted from 1991 to 1999 using the
same sample and measures as Galéra et al. (2008). Prevalence of smoking was estimated
according to three periods: lifetime, last 12 months, and last 30 days. Two dichotomous smoking
variables were created: 1) lifetime smoking variable (has ever used tobacco versus never used
tobacco; and 2) daily smoking variable (has smoked at least one cigarette per day over the last
year versus non-smoker). ADHD symptoms were not significant in the bivariate analysis with
lifetime smoking (Wald χ2 = 3.31, p = .07) or for daily smoking (Wald χ2 = 3.83, p = .05) for
males and were not significant in the adjusted model for lifetime smoking (OR = 1.50, p = .25)
or for daily smoking OR = 1.51, p = .27) for males. CD symptoms were not significantly related
to lifetime smoking (OR = 2.00, p = .06) but were significantly predicting daily smoking (OR =
2.95, p < .01) for males. ADHD symptoms were not significant in the bivariate analysis with
lifetime smoking (Wald χ2 = 1.15, p = .28) but were significantly related to daily smoking (Wald

χ2 = 9.25, p <.01) for females. ADHD symptoms were not significant in the adjusted model (OR
= 0.89, p = .74) for lifetime smoking but remained significant in the adjusted model for daily
smoking (OR = 1.98, p = .04) for females. CD symptoms significantly predicted lifetime
smoking (OR = 3.27, p < .01) but not daily smoking (OR = 1.75, p = .09) for females. ADHD
symptoms in childhood did not predict lifetime smoking in bivariate relationships for both males
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and females. ADHD symptoms contributed independently to subsequent daily smoking (OR =
1.98, p = .04) only for females. This sex difference is consistent with a population-based study
that analyzed ADHD and substance abuse (Disney et al., 1999). Reasons for results could be that
tobacco experimentation can be regarded as a normative experience rather than a deviant
behaviour. Thus, any association between ADHD symptoms and lifetime smoking is likely to
have been diluted in analyses taking into account the broad definition of smoking, and those
results were correspondingly biased toward the null hypothesis. A different picture emerged
when a more comprehensive definition of smoking was employed. For this reason, it is important
to use a more comprehensive definition of smoking, not just lifetime smoking.
In summary, most studies found a relationship between ADHD symptoms and tobacco cigarette
use, specifically regular tobacco cigarette use (Fergusson et al., 2007; Flory et al., 2003; Galéra
et al., 2013; Kollins et al., 2005; Sihvola et al., 2011; Upadhyaya & Carpenter, 2008). Fergusson
et al. (2007) found that rates of tobacco cigarette use increase significantly with increasing
ADHD symptoms. Flory et al. (2003), Galéra et al. (2013), Kollins et al. (2005), and Upadhyaya
and Carpenter (2008) found that ADHD symptoms made a significant and unique contribution
beyond that of covariates for increasing the odds of tobacco cigarette use. Furthermore, both
Galéra et al. (2005) and Sihvola et al. (2011) found that the relationship between ADHD
symptoms and tobacco cigarettes yielded sex specific results. Sihvola et al. (2011) found that the
risk of tobacco cigarette use in females with ADHD symptoms were higher than the risk in males
with ADHD symptoms. Galéra et al. (2005) found a significant relationship between ADHD
symptoms and daily tobacco cigarette use in females, but not in males. However, when Galéra et
al. (2005) also used a less stringent definition of smoking (lifetime smoking variable: has ever
used tobacco versus never used tobacco), they found that ADHD symptoms had no relationship
with lifetime smoking, for both males and females. Therefore, it is important to consider the use
of frequency measures as opposed to lifetime measures for this specific type of research.

2.5.3 Cannabis
Cannabis is one of the three substances most commonly used by youth (Barnes et al., 2009), and
has the highest prevalence of use after alcohol (Government of Canada, 2019). In 2018/19, 18%
of students in grades 7 through 12 reported using cannabis in the past 12 months (Government of
Canada, 2019). Students in grades 7 to 9 reported an increase in the use of cannabis (7%

28

compared to 6% in 2016/17); cannabis use among those in grades 10 to 12 remained unchanged
at 29% (Government of Canada, 2019). Some with ADHD report a preference for cannabis
(Mitchell et al., 2019), perhaps due to its anxiolytic properties (Bonn-Miller, Zvolensky, &
Bernstein, 2007). Similar to tobacco cigarette use, results from the literature regarding the
relationship between ADHD and cannabis use indicate that those with ADHD symptoms are
more likely to use cannabis than those with no ADHD symptoms.
Some studies indicate that ADHD symptoms are significantly associated with cannabis use
(Fergusson et al., 2007; Upadhyaya & Carpenter, 2008). Other studies did not find a significant
relationship between ADHD symptoms and cannabis use (Flory et al., 2003). Moreover, other
studies have found a relationship between ADHD symptoms and regular use of cannabis in
males (Galéra et al., 2008) but not regular use for cannabis in females or lifetime cannabis use
(Galéra et al., 2008) as well as a more apparent risk of cannabis use in females with ADHD
symptoms (Elkins et al., 2018).
Fergusson et al. (2007) examined the relationship between ADHD symptoms (measured using
the Attention Problem scale) and cannabis use. At age 18, 21, and 25, participants were asked
about cannabis use. Participants were classified as using cannabis if they reported using cannabis
at any time during the interval. Increasing attentional problems in middle childhood were
associated with increasing rates of cannabis use. Early CD symptoms and ADHD symptoms
proved to be correlated (r = .68; p < .0001). RR or OR were not produced. No sex differences
were discussed. Researchers assessed based on rates of cannabis use by symptoms (1 low, 2
symptoms, 3 symptoms, 4 symptoms, and 5 high symptoms). The report indicates that rates of
use increased significantly with increasing ADHD symptoms.
Upadhyaya and Carpenter (2008) assessed frequency of use in the past year for cannabis. The
number of ADHD symptoms were significantly related to past year cannabis use (OR = 1.14;
95% CI [1.06–1.24]). For every one symptom increase in ADHD, the odds of using cannabis at
least 5 times per week increased by 14%. For every one symptom increase in both hyperactive
and inattentive behaviours, the odds of using cannabis at least 5 times per week increased by
21% (OR = 1.21; 95% CI [1.03–1.42]) and 29% (OR = 1.29; 95% CI [1.13–1.47]), respectively.
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They found that ADHD symptoms were linked to greater cannabis use even after controlling for
CD symptoms. Lastly, ADHD symptomatology was unrelated to sex.
Flory et al. (2003) examined the relationship between ADHD symptoms and other childhood
disruptive behaviours with substance use in young adulthood and found that ADHD symptoms
did not make a significant and unique contribution beyond the addition of covariates for cannabis
use. Participants were asked questions regarding past year use of cannabis. Bivariate correlation
revealed that ADHD symptoms were significantly related to cannabis use (r = .17, p < .01) and
that CD symptoms were significantly related to cannabis use (r = .38, p < .01). ADHD symptoms
and CD symptoms were moderately correlated (r = .42, p < .01). Sex did not influence results in
the multiple regression analysis (sex did not modify the association between ADHD symptoms
and cannabis use). In the regression analyses for cannabis use, CD symptoms made a significant
and unique contribution, beyond that of ADHD symptoms. However, ADHD symptoms (OR =
1.01) did not make a significant and unique contribution beyond that of CD symptoms for
cannabis use. It is important to note that researchers used a significance level of p < .01 to
minimize the possibility of Type I error.
Elkins et al. (2018) and Galéra et al. (2008) found that the relationship between ADHD
symptoms and cannabis use yielded sex specific results. Elkins and colleagues (2018) examined
if childhood inattentive or hyperactive-impulsive symptoms predicted cannabis outcomes by age
17. Frequency of use was coded to reflect typical escalation during adolescence; for cannabis
frequency: 0 = never, 1 = less than once a month, 2 = once a month/nearly weekly, 3 =
weekly/daily. Adolescents with more ADHD symptoms were more likely to have higher
frequency of use. Overall effects were covariate-adjusted for age, parental SES, and sex. There
was evidence of effect modification by sex. When co-occurring use of other substances and
conduct/oppositional defiant symptoms were considered, hyperactivity-impulsivity and
inattention remained significant (p < .05). When sex differences were significant, ORs were
presented separately. ADHD inattentive symptoms were significantly related to the progression
toward daily cannabis use (OR = 1.20 (95% CI [1.13-1.28]), p < .001) and for lifetime cannabis
use (OR = 1.08, p < .001). ADHD hyperactivity-impulsivity symptoms were significantly related
to the progression toward daily cannabis use and this was significantly greater in females (OR =
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1.40 (95% CI [1.27-1.55]), p < .001) than males (1.19 (95% CI [1.08-1.31]), p < .001) (a result
of effect modification). ADHD hyperactivity-impulsivity symptoms were also significantly
related to lifetime cannabis use (OR = 1.08, p < .001). Hyperactivity-impulsivity effects were
associated more strongly with cannabis frequency (p = .02) for females than males. Each
hyperactive-impulsive symptom was associated with a 40% increase in odds for females (19%
for males) of progressing in cannabis frequency (e.g., weekly to daily).The risk of cannabis use
was more apparent in females (Elkins et al., 2018); reasons for this could be that females
experience greater social and academic consequences from ADHD symptoms than males (Elkins
et al., 2011) leading them to use cannabis as a way to cope with these consequences.
Galéra et al. (2008) examined cannabis use. For cannabis use, two variables were created: 1) a
lifetime cannabis smoking variable (has ever used cannabis versus never used cannabis); and 2) a
regular cannabis smoking variable (has smoked cannabis at least 10 times during the last 30 days
versus has smoked cannabis less than 10 times or has not smoked cannabis during the last 30
days). ADHD symptoms were not significant in the bivariate analysis with lifetime cannabis use
or in the regression analysis (OR = 1.54 95% CI [0.76-3.11]). ADHD symptoms were significant
in the bivariate analysis for regular cannabis use (p < .01). In males, ADHD symptoms had an
OR of 3.14 (95% CI [1.14-8.63], p = .03) for regular cannabis use even after controlling for
covariates (age, CD symptoms). In females, ADHD symptoms did not independently increase
the likelihood for regular cannabis use, whereas, low SES was predictive of regular cannabis use.
ADHD symptoms did not account for the risk of lifetime cannabis use. Owing to its relatively
high prevalence, cannabis experimentation cannot be considered as deviant behaviour.
Conversely, ADHD symptoms appeared to be a predictor of regular cannabis smoking in males
before and after adjusting for relevant covariates that included CD symptoms.
Studies have used lifetime measures for cannabis use (Elkins et al. 2018; Galéra et al. 2008);
however, lifetime measures do not differentiate those who used a substance once (i.e., due to
experimentation, which is defined as the mild initial use of a substance) from individuals who
use substances daily or frequently. A large proportion of youth have experimented with cannabis;
however, when lifetime measures are used, these youth are lumped into the same category as
those who use cannabis frequently or regularly. For example, according to an Australian survey,
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most teenagers seem to use cannabis infrequently: more than 50% used fewer than 10 times in
their life and 13% used 100 times or more in their life (Rey, Sawyer, Raphael, Patton, &
Lynskey, 2002).The National Drug Strategy Household Survey indicated that many youth who
have used cannabis (54% of those reporting lifetime use) appear to have stopped using it, or have
been using the substance infrequently (1-2 times per year) (Reid, Lynskey, & Copeland,
2000).This suggests that a high rate of lifetime cannabis use reflects a large amount of
experimental and irregular use that does not necessarily progress to regular or heavy use (Reid et
al., 2000). It is likely that this is not just the case for cannabis use as the utilization of lifetime
substance use measures does not capture the frequency of substance use. Hence, using a more
descriptive measure is necessary, given that when participants are categorized into one of two
response groups (i.e., those who use vs. those who do not use), there is likely to be significant
variability in substance use that is not reflected in the results (Lee et al., 2011) as there is likely
to be a significant difference between someone who has used a substance once in their lifetime
and someone who uses that substance every day. Thus, a more comprehensive measure is needed
when assessing the relationship between ADHD symptoms and any substance.
In summary, like tobacco cigarettes, most studies have found a relationship between ADHD
symptoms and cannabis use (Elkins et al. 2018; Fergusson et al., 2007; Galéra et al. 2008;
Upadhyaya & Carpenter, 2008). Additionally, Elkins et al. (2018) and Galéra et al. (2008) found
that the relationship between ADHD symptoms and cannabis yielded sex specific results. Elkins
et al. (2018) found that ADHD hyperactivity-impulsivity symptoms were significantly related to
the progression toward daily cannabis use and this was significantly greater in females than in
males; however, ADHD inattentive symptoms were significantly related to daily cannabis use
and lifetime cannabis use for both males and females and ADHD hyperactivity-impulsivity
symptoms were significantly related to lifetime cannabis use (Elkins et al., 2018). Conversely,
Galéra et al. (2008) found a relationship between ADHD symptoms and regular cannabis use in
males but not in females and no relationship between ADHD symptoms and lifetime cannabis
use regardless of sex. Finally, other studies did not find a relationship between ADHD symptoms
and cannabis use once CD symptoms were controlled for in the regression analysis (Flory et al.,
2003).
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2.5.4 Stimulants
In this study, the term “stimulants” refers to cocaine, crack-cocaine, ecstasy, and
methamphetamine use, unless stated otherwise. Scholars have debated whether youth with
ADHD would be more inclined to use stimulants as a form of self-medication to reduce ADHD
symptoms (Galéra et al., 2009) compared to other classes of substances, such as depressants,
because stimulant medications, such as methylphenidate, have shown positive therapeutic effects
on persons with ADHD (Arnsten, 2006). The strong clinical response of ADHD to dopaminergic
psychostimulant medication have raised questions about vulnerability to other dopaminergic
drugs (Lambert & Hartsough, 1998), including cocaine (McCabe, Veliz, Wilens, & Schulenberg,
2017).
When reviewing the literature, there is extensive research in this field on non-human samples
(such as gerbils, mice, and rats), studies on pregnancy and the effects of stimulant use during
pregnancy, and literature on pharmacological treatment for childhood ADHD; information
regarding ADHD symptoms and stimulant use among adolescents remains limited (Levin &
Kleber, 1995). When specifying the search key to exclude the examination of adults, all but a
couple of studies described non-human samples, studies on prenatal effects of stimulants, and
ADHD medical use of stimulants. The remaining studies had different key outcome variables
(e.g., excess mortality) or included stimulants as a risk factor to more popular substance use
(e.g., alcohol and tobacco cigarettes).
Although not ideal, this literature review on stimulants includes childhood ADHD and
subsequent adult use of cocaine (because of the lack of literature on childhood ADHD and
childhood cocaine use). Only one paper examined the relationship between ADHD symptoms
and cocaine use and whether those with ADHD symptoms are more likely to use cocaine than
those without ADHD symptoms (Galéra et al., 2013). Other studies have examined ADHD and
cocaine dependence (Lambert & Hartsough, 1998).
Galéra et al. (2013) assessed the link between childhood ADHD symptoms based on the
Attention Problem scale and cocaine use 18 years later in 1,103 French youth from 1991 to 2009.
In 2009, study participants were asked to report on their cocaine use. Lifetime cocaine use was
defined as one or more occasions. Galéra et al. (2013) found a significant relationship (OR =
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2.73) between ADHD symptoms and lifetime cocaine use in the adjusted model while
controlling for anxiety/depression symptoms, CD symptoms, and other demographic variables
(e.g., SES). Galéra et al. (2013) did not find an interaction of sex. Those who scored high > 90th
percentile for ADHD symptoms had a significant relationship with lifetime cocaine use (OR =
3.10 (95% CI [1.56-6.17]), p < .05 (adjusted for only age and sex)) even after fully adjusting for
covariates (OR = 2.73 (95% CI [1.16-6.45]), p < .05).
There is a lack of research on stimulants in youth probably due to the small percentage of youth
who engage in stimulants that are not popular substances (e.g., tobacco cigarettes). For example,
Loeber, Stouthamer-Loeber, and White (1999) examined alcohol, tobacco cigarettes, cannabis,
and other substances; however, because use rates were moderately low for these other
substances, analyses of these other substances were omitted. Since cell sizes are often too small
to analyze non-popular substances, scholars have integrated non-popular substances into “illicit
substances” without the consideration of substance class and how those with ADHD may be
more inclined to use stimulants than substances from another substance class. These results
should be interpreted cautiously as the robust relations of substances from one class may show
the opposite effect of the relations of substances from another class.
From this short review, it is evident that there is limited research on ADHD and stimulants. From
this one study that was assessed, there is a relationship between ADHD symptoms and lifetime
cocaine use. Galéra et al. (2013) found a significant relationship (OR = 2.73) between ADHD
symptoms and lifetime cocaine use in the adjusted model while controlling for CD and
anxiety/depression symptoms. Because there are so few studies on this subject matter, it is
evident that more research should be done in this area.

2.6 Socio-economic Status
Socioeconomic status (SES) is defined as the social standing or class of an individual or group
and is often measured as a combination of education, income, and occupation (APA, n.d.). SES
is thought to be related to both ADHD and substance use; hence it is necessary to consider SES
in any examination of the relationship between ADHD and substance use.
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According to a national health interview survey (data from 2011-2013) in the United States,
children and youth living in poverty have the highest rate of ADHD (CDC/NCHS, 2013). Studies
have suggested a correlation of variously defined measures of SES with ADHD, and a recent
systematic review and meta-analysis confirmed a small but reliable association (Russell, Ford,
Williams, & Russell, 2016). This systematic review examined 42 studies in their associations
between parental socioeconomic disadvantage and childhood ADHD. SES was measured by
parental income, education, occupation, and marital status. Of the 42 studies, 35 found a
significant univariate association between socioeconomic disadvantage and ADHD; on average,
children in families of low SES are 1.85-2.21 more likely to have ADHD than their peers in high
SES families. Furthermore, low SES increases the risk of child mental health problems (which
they divided between internalizing and externalizing disorders) by 1.18-3.34 times. Furthermore,
a study that included in the systematic review found that financial difficulties and a brief housing
tenure were significantly associated with ADHD, such that families either living in financial
difficulty or living in subsidized housing, were more likely to have a child with a diagnosis of
ADHD at age seven (Russell et al., 2015). Additionally, financial difficulties were the strongest
predictor of ADHD (OR 2.23 95% CI [1.57-3.16]) (Russell et al., 2015). Lastly, parent report of
financial difficulties was regressed on ADHD with adjustment for sex. Males comprised of
83.9% of the ADHD group (compared to females) and only 50.5% of the non-ADHD diagnosis
group.
Through the analysis of secondary data, studies have found that SES has also been associated
with substance use. A longitudinal population-based study (n=1,203; females 51.5%) from the
United States examined the associations of indicators of family SES (including income and
parental education) with smoking, alcohol use, and lifetime cannabis use in youth, utilizing data
from a household survey of families (Patrick, Wightman, Schoeni, & Schulenberg, 2012). Lower
SES was associated with subsequent smoking, and higher SES was associated with alcohol and
cannabis use in youth (Patrick et al., 2012). Another study used longitudinal, population-based
nationally-representative survey from the United States (National Longitudinal Survey of
Adolescent Health) with a total of 20,745 (males constituted 50.84%) students and their parents
who participated in-home interviews (Humensky, 2010) to conduct secondary analysis of the
relationship between SES and substance use. Substances were coded into lifetime use, and SES
was measured by parental education and income. Higher SES was associated with higher rates of
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binge drinking and cannabis use; however, no statistically significant results were found for
crystal methamphetamine or other substances (Humensky, 2010).
These two population-based studies suggest that research is inconsistent on whether the direction
of the relationship between SES and substance use is positive or negative (Hamilton et al., 2014);
however, most previous studies focused on lower SES populations (Humensky, 2010). Overall, it
is still important to examine SES when assessing the relationship between ADHD and substance
use, to observe if an adjusted model controlling for SES changes the relationship between
ADHD and substance use.

2.7 Social, Emotional, and Behavioural Problems
In the literature review section 2.5, researchers controlled for co-existing problems when
examining the relationship between ADHD symptoms and substance use by including social,
emotional, and behavioural problems as covariates in their analyses. Co-existing problems are
typically sorted into two groups, internalizing problems and externalizing problems. Internalizing
and externalizing problems are well-known concepts in the field of child psychology used to
describe two groupings of social, emotional, and behavioural problems (Jacob et al., 2014).
Internalizing problems refer to the internal psychological environment rather than the external
world in which distress manifests itself inward, and includes depression, anxiety, social
withdrawal, and emotional distress (Shin, Sung, Lim, Park, & Cho, 2012). Externalizing
problems refer to distress that manifests in outward behaviour (Jacob, et al., 2014), and consists
of aggressive and delinquent behaviours such as CD (Shin et al., 2012).
Studies indicate that youth with ADHD report higher levels of both internalizing problems (such
as anxiety and depression) and externalizing problems (such as aggression, delinquency, and
risk-taking) compared to their counterparts with typical development (McNamara, Willoughby,
& Chalmers, 2005; Wehmeier, Schacht, & Barkley, 2010). For example, Galéra et al. (2005)
found that those who reported ADHD symptoms were more likely to report CD symptoms than
those who did not report ADHD symptoms, as ADHD symptoms were highly correlated with
CD symptoms. Galéra et al. (2013) found that ADHD symptoms were significantly related to
both CD symptoms (r = 0.44, p < .05) and internalizing problems (such as being anxious or
depressed) (r = 0.36, p < .05). Furthermore, both Fergusson et al. (2007) and Flory et al. (2003)
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found that CD symptoms and ADHD symptoms proved to be correlated (r = .68, p < .0001; r =
.42, p < .01, respectively).
There is also research documenting strong associations between both internalizing and
externalizing problems and substance use (Winters, Stinchfield, Latimer, & Stone, 2009).
Externalizing problems, for example, were strongly associated with alcohol, tobacco cigarette,
and cannabis use among youth (n = 2,212; ages between 15 and 18 years) in a population-based
study conducted in Nordic countries (Pedersen et al., 2018). Studies utilizing population-based
samples have demonstrated that substance use such as alcohol is associated with both
internalizing and externalizing problems (Dawson, Goldstein, Moss, Li, & Grant, 2011). Galéra
et al. (2013) found that being anxious or depressed decreased the likelihood of using cocaine (r =
-0.08, p < .05) and that being anxious or depressed was significantly related to regular tobacco
cigarette use (OR = 0.85, 95% CI [0.73-0.99], p < .05) and lifetime cocaine use (OR = 0.48, 95%
CI [ 0.33-0.68], p < .05). Conversely, externalizing problems increased the chance of substance
use. Galéra et al. (2013) found that CD symptoms were significantly related to regular tobacco
cigarette use (OR = 1.35, 95% CI [1.19-1.54], p < .05) and lifetime cocaine use (OR = 1.39, 95%
CI [1.17-1.65], p < .05). Galéra et al. (2005) also found that CD symptoms were a significant
predictor for daily smoking (p < .01). Kollins et al. (2005) indicated that reporting higher
numbers of CD symptoms were significantly associated with the higher likelihood of regular
tobacco cigarette use. Lastly, Flory et al. (2003) found that CD symptoms were significantly
correlated with all substance use categories (alcohol use, tobacco cigarette use, and cannabis
use).
Some studies suggest that ADHD is associated with substance use through its comorbidity with
CD symptoms (Fergusson et al., 2007); the high interrelation between ADHD symptoms and CD
symptoms raises issues about the ways in which these domains of behaviour combine to
influence developmental outcomes (Fergusson et al., 2007). For example, Flory et al. (2003)
found that ADHD symptoms were no longer significantly related to daily cannabis use after
accounting for CD symptoms. Other studies have indicated that ADHD is associated
independently with substance abuse, in the adjusted model even after controlling for
internalizing problems and externalizing problems, and this was evident through the modelling
of covariates (Elkins, McGue, & Iacono, 2007; Galéra et al., 2008; Kollins et al., 2005;
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Upadhyaya & Carpenter, 2008). For example, Upadhyaya and Carpenter (2008) found that
ADHD symptoms were linked to greater substance use even after controlling for CD symptoms.
Sihvola et al. (2011) found that even after controlling for CD symptoms, ADHD symptoms
predicted frequent alcohol use. Kollins et al. (2005) found that the addition of CD symptoms
resulted in decreased ORs for ADHD symptoms, though both ADHD symptoms and CD
symptoms remained significant in the relationship with regular tobacco cigarette use. Likewise,
Galéra et al. (2008) found that ADHD symptoms appeared to be a predictor of regular cannabis
use in males even after adjusting for CD symptoms. Lastly, Galéra et al. (2013) found that after
controlling for both CD symptoms and anxious-depressed symptoms, ADHD symptoms
remained significantly related to both regular tobacco cigarette smoking (OR = 1.34, 95% CI
[1.13-1.58], p < .05) and lifetime cocaine use (OR = 1.47, 95% CI [1.10-1.97], p < .05).
Lee et al. (2011) concluded that internalizing problems and externalizing problems complicate
inferences about the specificity of ADHD effects on substance use outcomes. Lee et al. (2011)
strongly contended that these relationships be addressed by controlling for possible covariates.
Given the substantial correlation between ADHD symptoms and social, emotional, and
behavioural problems such as CD symptoms (Barkley, 2006) and anxious or depressed
symptoms (r = 0.36, p < .05) (Galéra et al., 2013), as well as the robust relations between
externalizing problems (Flory et al., 2003) and internalizing problem with substance use
(Dawson et al., 2011; Galéra et al., 2013), any conclusions regarding ADHD and substance use
suggested from studies that do not control for social, emotional, and behavioural problems
should be interpreted cautiously. Failure to analyze an adjusted model to control for internalizing
and externalizing problems can lead to erroneous conclusions about the relationship between
ADHD and substance use. Therefore, it is important to address the possibility of covariates
within the relationship of ADHD and substance use in youth.

2.8 Study Objectives
The overall goal of the current study was to better understand the relationship between ADHD
symptoms and substance use by assessing the relationship between these two variables in a
population-based sample of Ontario students (grades 9-12). The specific objectives of this thesis
were:
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1. to estimate the prevalence of ADHD symptoms in a representative sample of students in
Ontario schools, including the prevalence for both males and females separately;
2. to assess the relationship between ADHD symptoms and substance use (alcohol, tobacco
cigarettes, cannabis, and stimulants1), running two separate models for males and females:
a. Model 1: unadjusted model - to estimate effect of ADHD symptoms on the risk of
substance use. This model aims to provide a baseline understanding of the relationship
between ADHD symptoms and substance use without adjusting for any covariates.
b. Model 2: adjusted model - to examine the effect of ADHD symptoms on the risk of
substance use accounting for SES, internalizing problem, and externalizing problem.
This model aims to assess if (and how) the relationship between ADHD symptoms and
substance use changes after adjusting for covariates.

2.8.1 Hypotheses
It is hypothesized that the estimates of prevalence of ADHD symptoms from this study will be
higher than all the prevalence estimates of ADHD that are based on actual diagnoses from a
clinician; these estimates in Canada range from 1.5% (Brownell & Yogendran, 2001) to 5.4%
(Hauck et al., 2017).
In the literature, the lower prevalence estimates came from studies that used administrative
medical records (Brault & Lacourse, 2012; Brownell & Yogendran, 2001; Vasiliadis et al., 2017)
and the higher prevalence estimates came from studies using a symptom checklist (Green et al.,
2019; Madruga et al., 2012; Polanczyk et al., 2010; Sonnby et al., 2011; Szatmari et al., 1989). It
is possible that studies that used a symptom checklist to measure ADHD produced larger
prevalence statistics compared to studies that used administrative medical records because
symptom checklists are more inclusive (could be capturing broader spectrum of psychological
symptoms), whereas diagnoses based on DSM criteria by physicians or psychologists are more
exclusive (as these ADHD symptoms should not be better explained by another mental disorder

1

In this study, the term “stimulants” refers to cocaine, crack-cocaine, ecstasy, and methamphetamine use, unless
stated otherwise.
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such as a mood disorder). Furthermore, clinicians, such as physicians, and psychologists try to
eliminate other disorders that could account for the symptoms and assess functional impairment
in two or more domains that are not typically captured in survey symptom checklists. Finally,
studies of ADHD based on clinician diagnoses suffer from referral bias.
In terms of the second objective, it is difficult to hypothesize potential outcomes since the
literature has produced conflicting evidence on the relationship between ADHD and substance
use (with alcohol, tobacco cigarettes, cannabis, and stimulants), especially when accounting for
covariates. When covariates are accounted for in the model, it is hypothesized that ADHD will
be related to some substances but not others, similar to the results that Flory et al. (2003) found
when controlling for covariates. Based on the literature, it is hypothesized that the relationship
between ADHD symptoms and substance use will present differently for the two sexes (Elkins et
al., 2018; Galéra et al., 2005; Galéra et al., 2008; Sihvola et al., 2001) and based on the papers
reviewed, it is hypothesized that ADHD symptoms will be statistically significantly related to
substance use in females, but not in males.
This study offers a unique contribution to the literature by providing recent Canadian prevalence
estimates of self-reported ADHD symptoms by sex from a population-based school study in
Ontario and by examining the relationship between self-reported ADHD symptoms and
substance use of both popular substances and stimulants by sex, as most research has been
conducted on the most popular substances (alcohol, tobacco cigarettes, and cannabis). Lastly,
SES and social, emotional, and behavioural problems are thought to be related to both ADHD
and substance use. Thus, it is important to control for sociodemographic factors including SES,
as well as for possible co-occurring problems such as internalizing and externalizing problems so
that it is evident if ADHD symptoms are in fact related to substance use or if the relationship we
see is confounded by covariates. Therefore, this study provides a unique contribution to the
literature by controlling for factors associated with both ADHD and substance use.
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Chapter 3

3

Methods

3.1 Study Design
This study was a secondary data analysis conducted using cross-sectional data from the Centre
for Addiction and Mental Health (CAMH). The data included two cycles/waves of the Ontario
Student Drug Use and Health Survey (OSDUHS): the 2015 and 2017 OSDUHS public datasets.
The OSDUHS is a large ongoing population-based survey of Ontario adolescents.

3.2 Data Source
All measures were derived from the OSDUHS. The OSDUHS is a biennial survey that first
started in 1977. The survey focuses on reporting substance use, and physical and mental health
outcomes of students in Ontario. For the 2015 dataset, questionnaires were collected from
November 2014 to June 2015 (Boak, Hamilton, Adlaf, Henderson, & Mann, 2016). For the 2017
dataset, questionnaires were collected from November 2016 to June 2017 (Boak, Hamilton,
Adlaf, Henderson, & Mann, 2018). The data were self-reported, derived from anonymous
questionnaires administered in classrooms via a paper-and-pencil instrument, to students who
consented and whose parents provided active parental consent. There were four split ballot
versions of the questionnaire (Form A-ES, Form B-ES, Form A-SS, Form B-SS), which each
averaged 30 minutes to complete and were administered by trained staff from the Institute for
Social Research (York University, Ontario). Form A and Form B were randomly distributed to
students such that one-half of students completed Form A and the other half completed Form B.
Forms ending in “ES” were for those in grade 7 and 8 to complete, while forms ending in “SS”
were for those in grade 9 to 12 to complete.
Survey respondents were selected by a stratified (region by school level), two-stage cluster
sampling design. Region refers to the way that Ontario was divided; there are four base regions
and seven regions deemed fit to oversample by Ontario Public Health. So, in total there are 11
mutually exclusive regions in Ontario and seven of these regions were oversampled. Schools
within each of these regions were selected by probability-proportionate-to-school size while
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classes were selected with equal probability. Both stages employed sampling without
replacement. This disproportionally stratified method involved the oversampling of those in
northern Ontario in order to provide a more precise estimate for that less populous region. This
design ensured that the regional comparison tests have sufficient statistical power and that
numbers generated from this study (including prevalence statistics and relative risk ratios) were
representative through complex weighting of the sample and using census data (Boak et al.,
2016). For the 2015 questionnaire, 63% of selected schools, 88% of selected classes, and 59% of
students in participating classes participated in the survey. The 2015 total sample of 10,426
students is representative of the 961,500 grade 7 to 12 students enrolled in Ontario’s publicly
funded public and Catholic schools. For the 2017 questionnaire, sixty-one percent (61%) of
randomly selected schools, 94% of selected classes, and 61% of eligible students in those classes
completed the survey. The 2017 total sample of 11,435 students represents just under one million
students in grades 7 to 12 enrolled in Ontario’s publicly funded schools (Boak et al., 2016).
The population of the current study was students enrolled in Ontario’s four publicly funded
school systems (English language public, English language Catholic, French language public,
and French language Catholic). Students were not included if they were enrolled in private
schools, were home-schooled, were on military bases, lived in First Nations communities, were
institutionalized for correctional or health reasons, or lived in remote northern regions of Ontario
(Boak et al., 2016). Those excluded from the survey’s target population represented a small
proportion of roughly 8% of the Ontario student population; therefore, the vast majority of
Ontario children and adolescents were captured in the survey (Boak et al., 2016).

3.3 Study Sample
Based on the adopted inclusion criteria, the current study included all respondents who provided
valid responses to Form A-SS (grade 9-12) from the 2015 and 2017 cycle of the CAMH
OSDUHS (only secondary students (grades 9 through 12) were asked questions regarding
cocaine, crack-cocaine, ecstasy, and methamphetamine use). Also, the A-SS Form was the only
form that included all questions relevant to this study, such as the Adult ADHD Self-Report
Scale Version 1.1 (ASRS-v1.1 Screener), the Kessler 6-Item Psychological Distress Scale (K6
Screener), the Antisocial Behaviour Index, and stimulant use questions. Data from the 2015 and
2017 datasets were pooled to increase the sample sizes, as use of stimulants were rare. A total of
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7,724 adolescent Ontarians filled out Form A-SS from the 2015 and 2017 cycle; however, 801
participants were removed due to missing data pertaining to the variables of interest for this
current study, resulting in a final sample size of 6,923 (see figure 1).
Fig. 1: Flowchart of Sample Selection

3.4 Measures
The OSDUHS questionnaire utilizes some standard measures and methods that have gone
through rigorous testing to ensure the demonstration of validity and reliability (Boak et al.,
2016). Additionally, for studies that include sensitive and taboo topics such as substance use,
data collected through anonymous, self-reported, school-based surveys demonstrate higher
credibility than other data collecting methods (such as surveys completed at home), since
perceived anonymity in the absence of parental company may lead these adolescents to be more
honest with their responses (Brener et al., 2006). Lastly, the readability of the 2015 questionnaire
indicated a grade 7 reading level according to the Flesch-Kincaid reading score (Boak et al.,
2016). Table 1 displays all variables of interest in the present study. In the text below variables
were referred to by their variable name (in brackets) in the 2017 dataset (however, bridged
variable names were created for 2015 and 2017 datasets for the analysis).
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Table 1: Study Variables
Variable and Type

Measurement

Missing Data (%)

Scores of 14 or higher on the
ASRS-v1.1 Screener
1 = Yes
0 = No

193 (2.50%)

Exposure Variable
ADHD Symptoms (J3a-J3f)
Dichotomous
Outcome Variables
Alcohol Use (b3)
Trichotomous

1 = “No use”
2 = “Occasional use”
3 = “Regular use”

Tobacco Cigarette Use (b1)
Trichotomous

1 = “No use”
2 = “Occasional use”
3 = “Regular use”

Cannabis Use (b4)
Trichotomous

1 = “No use”
2 = “Occasional use”
3 = “Regular use”

Stimulant Use (aggregation of b10-s,
b11-s, b12-s, and b13-s)
Trichotomous

1 = “No use”
2 = “Occasional use”
3 = “Regular use”

37 (0.48%)

Sex (a2)
Dichotomous

1 = Male
0 = Female

No Missing Values

SES (a20)
Trichotomous Nominal

1 = low
2 = middle
3 = high

121 (1.57%)

Internalizing Problem (j2a-j2f)
Dichotomous

Scores of 13 or higher on K6
Screener
1 = Yes
0 = No

181 (2.34%)

Externalizing Problem (m1a-m1j)
Dichotomous

Three or more behaviours on
the Antisocial Behaviour
Index
1 = Yes
0 = No

334 (4.32%)

15 (0.19%)

13 (0.17%)

48 (0.62%)

Covariates
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3.4.1 ADHD Symptom Measure
ADHD symptoms were measured using the validated WHO’s ASRS-v1.1 Screener. The ASRSv1.1 Screener (refer to Appendix 1) is a six-item checklist (J3a-J3f) used to assess ADHD
symptoms based on DSM-IV criteria for ADHD. The first four questions pertain to inattention,
whereas the last two questions pertain to hyperactivity-impulsivity. Each item is scored on a 5point frequency Likert-type scale (0= never; 4= very often). Assessment of the six screener items
indicated good internal consistency (α=0.79); however, a high internal consistency was unlikely,
as a stepwise logistic regression analysis was used to select all six screener questions. This
method optimized inconsistency among items so that there was no overlap or repetition in a
single screener. Kessler et al. (2007) also assessed test-retest reliability by administering the
ASRS-v1.1 Screener at baseline, six months to one year after baseline, and again one to three
months after the second screening. The ASRS-v1.1 Screener had a test-rest reliability ranging
from .58-.77 (Kessler et al., 2007). The 0-24 scoring approach demonstrated high concurrent
validity, as the ASRS-v1.1 Screener had a strong concordance with clinical diagnosis, achieving
an area under the receiver operating characteristic curve (AUC) of 0.90 (Kessler et al., 2007).
Furthermore, Kessler et al. (2007) indicated that this screener had a sensitivity of 0.65,
specificity of 0.94, a positive predictive value (PPV) of .50, and a negative predictive value
(NPV) of .97. The screener had a total classification accuracy of 0.92 (SE = 0.38) (Kessler et al.,
2007).
The ASRS-v1.1 Screener was first developed for population health surveys involving adults
(Kessler et al., 2007); however, the screener has also been used in research with adolescents
(Green et al., 2019; Madruga et al., 2012; Polanczyk et al., 2010; Sonnby et al., 2011). Though
the screener has been used with adolescents, the questions involved in this screener were more
applicable to adults than adolescents. Lastly, it is important to remember that this instrument is a
screener and should not be considered as a clinical diagnosis (Boak et al., 2018).
Two validation studies were conducted on the ASRS-v1.1 Screener in adolescents (Adler et al.,
2012; Green et al., 2019). Adler et al. (2012) conducted a preliminary examination of reliability
and concurrent validity of the ASRS-v1.1 Screener in adolescents with ADHD, whereas, Green
et al. (2019) examined reliability and validity of the ASRS-v1.1 Screener among community
samples of adolescents. Internal consistency for the total sample and in subsamples stratified by
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sex and grade level using Cronbach’s alpha were assessed to gauge reliability. To determine
convergent and divergent validity, correlation coefficients were compared to the screener sum
score to each subscale of the Strengths and Difficulties Questionnaire (SDQ). The SDQ is a 25item measure of student social-emotional strengths and challenges producing five subscales:
hyperactivity/inattention, emotional problems (i.e., anxiety and depression), conduct problems,
peer problems, and prosocial behaviours. Prior studies documented reliability of the SDQ and
validity in comparison with structured diagnostic interviews (Goodman, 2001). The ASRS-v1.1
Screener demonstrated good internal consistency in the total sample (α=0.80). Reliability was
also good in subsamples stratified by gender and grade. The model also fit the data well for both
males and females separately and for both middle and high school students separately. The
ASRS-v1.1 Screener scores were more strongly associated with the SDQ subscales measuring
hyperactivity/inattention (r = 0.58) than all other subscales, which measured emotional problems
(r = 0.41, p < .001), conduct problems (r = 0.35, p < .001), etc.
There are several proposed approaches to score the ASRS-v1.1 Screener. Kessler recommended
utilizing the four-stratum classification approach based on psychometric analyses (Kessler et al.,
2007), as opposed to the 0-6 scoring approach which was found to be less discriminative. For the
purpose of this study, a summated score (with a range of 0 to 24) was computed for those who
answered all six items. Reported ADHD symptoms were measured as a binary variable based on
the cut off score of 13 (0-13=0; 14-24=1) (Kessler et al., 2007).

3.4.2 Substance Use Measures
The key outcome variables used to assess the second objective were based on questions related
to self-reported frequency of substance use. The standard frequency of use question was used to
measure all substances of interest. The substance use questions of interest on the OSDUHS were
taken from the National Survey on Drug Use and Health (NSDUH). The NSDUH was one of the
primary sources of data for population-based prevalence estimates of mental health and
substance use indicators in the United States (Hedden et al., 2012). The reliability statistics
among persons aged 12 or older can be found in the 2006 NSDUH Reliability Study (tables on
page 58- 64) (Substance Abuse and Mental Health Services Administration, 2010). Diagnostic
and validation studies have been conducted on substance use measures from the NSDUH (Centre
for Behavioral Health Statistics and Quality, 2014). The kappa values for the standard frequency
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of substance use questions were for how often one used substances in the “past year”. These
“past year” substance use variables showed good reliability and all kappa’s were greater than .60,
which indicates substantial agreement among raters (Substance Abuse and Mental Health
Services Administration, 2010).
Based on the results of the preliminary analysis, it was noted that not every substance could be
examined on its own due to small cell sizes. For instance, the examination of heroine use could
not be done, as preliminary data suggested that only 24 (0.35%) of the 6,923 participants in this
sample used heroin. Furthermore, few of those participants who reported using heroin reported
symptoms of ADHD. Thus, all stimulants with large enough cell sizes (cells with at least 10
cases) were aggregated into one class: stimulants (cocaine, crack-cocaine, ecstasy, and
methamphetamine). It was important that these measures reflected the distinct pharmabehavioural features of this class of substance, by labelling and including only stimulants in the
“stimulant” category. In addition, popular substances were examined individually (alcohol,
tobacco cigarettes, cannabis) as there were sufficient data to carry out these analyses.

3.4.2.1
3.4.2.1.1

Popular Substances
Alcohol Use

Alcohol use (variable b3) was measured with the following question: “In the last 12 months, how
often did you drink alcohol-liquor (rum, whiskey, etc.), wine, beer, coolers?”. Frequency of
alcohol use was measured on a 10-point scale: “had a sip of alcohol to see what it’s like” (coded
1), “drank only at special events (for example, holidays or at weddings)” (coded 2), “once a
month or less often” (coded 3), “2 or 3 times a month” (coded 4), “once a week” (coded 5), “2 or
3 times a week” (coded 6), “4 or 5 times a week” (coded 7), “almost every day- 6 or 7 times a
week” (coded 8), “drank, but not in the last 12 months” (coded 9), and “never drank alcohol in
lifetime” (coded 10). The standard question for alcohol use was taken from the NSDUH. The
inter-rater reliability statistic (kappa) for past year use of alcohol was .85 (SE = .02) (Substance
Abuse and Mental Health Services Administration, 2010).
For the purpose of this study, alcohol use was recoded into three categories: (1) “no use”
(aggregating “had a sip of alcohol to see what it’s like”, “drank, but not in the last 12 months”
and “never drank alcohol in lifetime”); (2) “occasional use” (aggregating “drank only at special
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events (for example, holidays or at weddings)” and “once a month or less often”); and (3)
“regular use” (aggregating “2 or 3 times a month”, “once a week”, “2 or 3 times a week”, “4 or 5
times a week”, and “almost every day- 6 or 7 times a week”) (Hamilton et al., 2014).

3.4.2.1.2

Tobacco Cigarette Use

Tobacco cigarette use (variable b1) was measured with the following question: “In the last 12
months, how often did you smoke tobacco cigarettes?”. Frequency of tobacco cigarette use was
measured on a 11-point scale, including: “smoked a few puffs to a whole cigarette in the last 12
months” (coded 1), “smoked more than one cigarette, but not every day” (coded 2), “1 or 2
cigarettes a day” (coded 3), “3 to 5 cigarettes a day” (coded 4), “6 to 10 cigarettes a day” (coded
5), “11 to 15 cigarettes a day” (coded 6), “16 to 20 cigarettes a day” (coded 7), “21 to 29
cigarettes a day” (coded 8), “30 or more cigarettes a day” (coded 9), “smoked, but not in the last
12 months” (coded 10), and “never smoked cigarettes in lifetime” (coded 11). The standard
question for frequency of tobacco cigarette use was from the NSDUH. The inter-rater reliability
statistic (kappa) for past year use of cigarettes was .90 (SE = .02) (Substance Abuse and Mental
Health Services Administration, 2010).
To be consistent with the measure of alcohol use, tobacco cigarette use was recoded into three
categories: (1) “no use” (aggregating “smoked a few puffs to a whole cigarette in the last 12
months”, “smoked, but not in the last 12 months”, and “never smoked cigarettes in lifetime”); (2)
“occasional use” (“smoked more than one cigarette, but not every day”); and (3) “regular use”
(aggregating “1 or 2 cigarettes a day”, “3 to 5 cigarettes a day”, “6 to 10 cigarettes a day”, “11 to
15 cigarettes a day”, “16 to 20 cigarettes a day”, “21 to 29 cigarettes a day”, and “30 or more
cigarettes a day”).

3.4.2.1.3

Cannabis Use

Cannabis use (variable b4) was measured with the following question: “In the last 12 months,
how often did you use cannabis (also known as marijuana, “weed”, “pot”, “grass”, hashish,
“hash”, hash oil, etc.)?”. Frequency of cannabis use was measured on a 9-point scale: “1 or 2
times” (coded 1), “3 to 5 times” (coded 2), “6 to 9 times” (coded 3), “10 to 19 times” (coded 4),
“20 to 39 times” (coded 5), “40 or more times” (coded 6), “used, but not in the last 12 months”
(coded 7), “never used in lifetime” (coded 8), and “don’t know what cannabis is” (coded 9). The
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standard question for frequency of cannabis use was from the NSDUH. The inter-rater reliability
statistic (kappa’s) for past year use of cannabis was .75 (SE = .04) (Substance Abuse and Mental
Health Services Administration, 2010).
Cannabis use was recoded into three categories: (1) “no use” (aggregating “used, but not in the
last 12 months”, “never used in lifetime”, and “don’t know what cannabis is”); (2) “occasional
use” (“1 or 2 times”); and (3) “regular use” (aggregating “3 to 5 times”, “6 to 9 times”, “10 to 19
times”, “20 to 39 times”, and “40 or more times”).

3.4.2.2

Stimulants

Stimulants speed up activity in the body by improving alertness and energy, although when
abused, stimulants cause a “high” feeling (The Department of Health, 2004). Hence, stimulants
may have positive cognitive effects on persons with ADHD. Stimulants include cocaine, crackcocaine, ecstasy, and methamphetamine. Crack-cocaine is a highly addictive and powerful
stimulant derived from powdered cocaine and is inexpensive, and thus accessible; ingesting
crack-cocaine will cause an intense euphoric effect. Ecstasy (also known as MDMA) is primarily
considered a stimulant, although it is a substance with both stimulant and hallucinogenic
properties; symptoms include mild hallucinogenic effects, increased tactile sensitivity,
dehydration, and impaired memory. Methamphetamine (also known as speed, crystal meth, or
ice) is a stimulant that produces powerful “highs” similar to cocaine, but it can last much longer.
A limited amount of research regarding the different ways to categorize stimulant use exists. For
the sake of consistency, stimulant use was recoded into three categories: (1) “no use”
(aggregating “used, but not in the last 12 months”, “never used in lifetime” and “don’t know
what these drugs are”); (2) “occasional use” which consists of 1 or 2 times in the last 12 months;
and (3) “regular use” (aggregating “3 to 5 times”, “6 to 9 times”, “10 to 19 times”, “20 to 39
times”, and “40 or more times”). The empirical distribution was examined after selecting a
theoretical distribution that were trichotomized into no uses, occasional use, and regular use.
Although most participants fall into the (1) “no use” category, the distribution between (2)
“occasional use” and (3) “regular use” were comparably similar.
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New variables were generated by aggregating the stimulants by class, as the OSDUHS does not
identify stimulant use by class. There are primarily two issues with previous research on
stimulants. Most prior research grouped all types of illicit substances under one general umbrella
term, thereby including stimulants, depressants, etc. in the same category. Next, most prior
research used binary measures, most likely due to small cell sizes. Fischer et al. (2013), for
example, aggregated eight substances (mushrooms, LSD, cocaine, crack, methamphetamine,
ecstasy, prescription stimulant drugs used non-medically, and prescription
tranquillizers/sedatives used non-medically) under one general substance term, even though
these substances included a mix of stimulants, hallucinogens, and depressants; this was re-coded
as: use of any one of the eight substances at least once during the past 12 months (1), no use (0).
Similarly, other papers conceptualized substance use as: “use of at least one of the 24 substances
in the past 12 months” (1) and “no use” (0), and this included “illicit substances” across the three
substance classes (stimulants, hallucinogens, and depressants) as well as non-medical
prescription substance use (Isaranuwatchai et al., 2014). One paper, however, examined
stimulant and tranquillizer medication as two separate classes (Pulver, Davison, & Pickett,
2014). Those who reported past-year recreational use of one or more medications, 3 or more
times were further categorized as “regular use”, while those reporting using 1-2 times were
categorized as “occasional use”. This method of categorization has been previously used in
OSDUHS and this is the same method that was employed in this current study.
Since whether a greater percentage of those with reported ADHD symptoms use stimulants
regularly or occasionally, compared to those with no reported ADHD symptoms is of interest for
this current study, binary measures (no use [0] vs. used at least once [1]) would be an insufficient
method, as the saliency of use would not be captured. Data on aggregating stimulant use
variables according to substance class is sparse and justification for categorization of response
variables is even more sparse. To be consistent with Pulver et al. (2014) and with the measure of
alcohol use, tobacco cigarette use, and cannabis use in this current study, stimulant use was
measured by frequency.
The following four stimulants (cocaine, crack-cocaine, ecstasy, and methamphetamine) were
aggregated under the substance class “stimulants”. It was assumed that all stimulants in this class
were equal, so the weight on all stimulants within “stimulant use” was equal. Each participant’s

50

response was aggregated across the four stimulants to create a new dependent variable. The
highest-level ranking score was assigned for each participant. For example, if a participant
recorded occasional use of cocaine, crack-cocaine, and methamphetamine, but recorded regular
use of ecstasy, this participant was assigned with an overall regular use of stimulants.
Preliminary analyses to examine the distribution of stimulants across all three categories by sex
were run; cell sizes were above the recommended cell size of 30 and the absolute minimum case
of 10 per independent variable.

3.4.2.2.1

Cocaine Use

Cocaine use (variable b10-s) was measured with the following question: “In the last 12 months,
how often did you use cocaine (also known as “coke”, “blow”, “snow”, “powder”, “snort”,
etc.)?”. All stimulants were measured on the same 9-point scale: “1 or 2 times” (coded 1), “3 to 5
times” (coded 2), “6 to 9 times” (coded 3), “10 to 19 times” (coded 4), “20 to 39 times” (coded
5), “40 or more times” (coded 6), “used, but not in the last 12 months” (coded 7), “never used in
lifetime” (coded 8), and “don’t know what drug is” (coded 9). The standard question for the
frequency of cocaine use was taken from the NSDUH. The inter-rater reliability statistic (kappa)
for past year use of cocaine was .78 (SE = .06) (Substance Abuse and Mental Health Services
Administration, 2010).

3.4.2.2.2

Crack-cocaine Use

Crack-cocaine use (variable b11-s) was measured with the following question: “In the last 12
months, how often did you use cocaine in the form of “crack”?”. There are a total of 9 response
options, including: “1 or 2 times” (coded 1), “3 to 5 times” (coded 2), “6 to 9 times” (coded 3),
“10 to 19 times” (coded 4), “20 to 39 times” (coded 5), “40 or more times” (coded 6), “used, but
not in the last 12 months” (coded 7), “never used in lifetime” (coded 8), and “don’t know what
“crack” is” (coded 9). The standard question for frequency of crack-cocaine use was from the
NSDUH. The inter-rater reliability statistic (kappa) for past year use of stimulants was .72 (SE =
.09) (Substance Abuse and Mental Health Services Administration, 2010). The inter-rater
reliability statistic for past year use of crack-cocaine use was not available.
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3.4.2.2.3

Ecstasy Use

Ecstasy (b12-s) use was measured with the following question: “In the last 12 months, how often
did you use MDMA or “Ecstasy” (also known as “molly”, “E”, “X”)?”. There were a total of 9
response options, including: “1 or 2 times” (coded 1), “3 to 5 times” (coded 2), “6 to 9 times”
(coded 3), “10 to 19 times” (coded 4), “20 to 39 times” (coded 5), “40 or more times” (coded 6),
“used, but not in the last 12 months” (coded 7), “never used in lifetime” (coded 8), and “don’t
know what “ecstasy” is” (coded 9). The standard question for frequency of ecstasy use was from
the NSDUH. The inter-rater reliability statistic (kappa) for past year use of stimulants was .72
(SE = .09) (Substance Abuse and Mental Health Services Administration, 2010). The inter-rater
reliability statistic for past year use of ecstasy use was not available.

3.4.2.2.4

Methamphetamine Use

Methamphetamine use (variable b13-s) was measured with the following question: “In the last
12 months, how often did you use methamphetamine or crystal methamphetamine (also known
as “speed”, “crystal meth”, “crank”, “ice”, etc.)?”. There were a total of 9 response options,
including: “1 or 2 times” (coded 1), “3 to 5 times” (coded 2), “6 to 9 times” (coded 3), “10 to 19
times” (coded 4), “20 to 39 times” (coded 5), “40 or more times” (coded 6), “used, but not in the
last 12 months” (coded 7), “never used in lifetime” (coded 8), and “don’t know what these drugs
are” (coded 9). The standard question for frequency of methamphetamine use was from the
NSDUH. The inter-rater reliability statistic (kappa) for past year use of stimulants was .72 (SE =
.09) (Substance Abuse and Mental Health Services Administration, 2010). The inter-rater
reliability statistic for past year use of methamphetamine use was not available.

3.4.3 Sex
Sex at birth (variable a2) was measured with the following question: “Were you born male or
female?”. There were 2 response options, including: “male” (coded 1) and “female” (coded 0).

3.4.4 Socio-economic Status Measure
For the purpose of this study, subjective SES was measured by the MacArthur Scale of
Subjective Social Status (SSS) (Goodman et al., 2001; Goodman, Huang, Schafer-Kalkhoff, &
Adler, 2007; McLaughlin, Costello, Leblanc, Sampson, & Kessler, 2012). The questionnaire
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showed a 10-rung ladder to symbolize the social hierarchy of Canadian society. Students were
asked to choose which rung most represented their family’s place in society with respect to
money, education, and occupation. The higher the rung, the higher the perceived family SESmore money, higher education, and highly respected occupations. Rungs 1-5 represented low
family SSS (Boak et al., 2018). Rungs 6-8 represented average SES. Rungs 9-10 represented
high SES. SES was measured as a categorical variable using the same three categories (low SES:
rungs 1-5; middle SES: rungs 6-8; and high SES: rungs 9-10) used in analysis in the CAMH
2017 mental health report (Boak et al., 2018).

3.4.5 Internalizing Problem Measure
The Kessler 6-Item Psychological Distress Scale (K6 Screener) (refer to Appendix 2) is a selfreport screening instrument that contains questions pertaining to recent symptoms of anxiety,
such as feeling nervous, hopeless, restless or fidgety and recent symptoms of depression, such as
feeling depressed (sad) that nothing could cheer you up, that everything was an effort, and
feeling worthless. Each of the six items in the K6 Screener began with the wording “In the last 4
weeks, about how often did you…”. This screening instrument (j2a-j2f) was designed to detect
non-specific psychological distress (symptoms of anxiety and depression) (Kessler et al., 2003),
which provided a measure of internalizing problem. The K6 Screener was originally developed
and calibrated for population health surveys of adults; however, it has also been used in research
with adolescents (Chan & Fung, 2014; Green, Gruber, Sampson, Zaslavsky, & Kessler, 2010;
Peiper, Clayton, Wilson, & Illback, 2015). Assessment of the six scale items indicated excellent
internal consistency (α=0.88) (Kessler et al., 2002).
The K6 Screener has been compared to the K10, the WHO Disability Assessment Schedule, and
the composite international diagnostic interview short-form scale (Kessler et al., 2003). Of these
scales, the K6 Screener was the most efficient screening scale, with a sensitivity of 0.36 (0.08)
and a specificity of 0.96 (0.02) in predicting serious distress and total classification accuracy of
0.92 (0.02); this pertains to the cut-off point of 13 or higher (Kessler et al., 2003). Studies have
examined the psychometric properties of the K6 Screener in large general population samples of
adolescents (N= 4,434; mean age =13.5 years; 44.6% male) (Mewton et al., 2016). Here, the K6
Screener demonstrated high levels of internal consistency, with the 6 items loading primarily on
1 factor. In summary, the K6 Screener is brief, easy to administer, and has shown excellent
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accuracy and specificity in samples from the general population (Swartz & Lurigio, 2006).
Validation studies have shown that the screener’s validity (ROC-AUC) was about .86, which is
quite high as compared to longer diagnostic screening and assessment instruments (Andrews &
Slade, 2001; Furukawa, Kessler, Slade, & Andrews, 2003; Kessler et al., 2003).
Each item was scored on a 5-point frequency Likert-type scale (0= none of the time; 4= all of the
time). Then, a summed score (with a range of 0 to 24) was computed for those who answered all
six items. Higher scores indicated higher levels of psychological distress. The use of severity
scoring allowed greater specificity as compared to yes/no dichotomized response options.
Kessler and colleagues (2002) suggestion for K6 Screener cut-off score of 13 or higher was
adopted for this study to estimate the percentage experiencing severe psychological distress (012=0; 13-24=1), meaning those who scored 13 or higher were considered as having
“internalizing problem” and those who scored below 13 were considered as not having
internalizing problem.

3.4.6 Externalizing Problem Measure
The measure of externalizing problem (refer to appendix 3) was obtained from the MTF study
(Monitoring the Future, n.d.). This included 10 questions (m1a-m1j) on recent delinquent activity
such as “damage something on purpose that wasn’t yours” and “beat up/hurt anyone (not
counting sibling).” These 10 questions involved both nonviolent behaviours and violent
behaviours. This measure encompassed an open-ended format to indicate the number of
occasions during the past 12-month period in which students engaged in these activities.
Response options were re-coded into ordinal categories. Psychometrics for this measure do not
exist and no tests regarding validity or reliability have been conducted thus far. This is a
limitation, but a strength of the MTF is the development of a standardized scoring method (the
antisocial behaviour index).
The antisocial behaviour index was created in 1991 (index excludes setting something on fire
(m1j) which results in a total of nine behaviours instead of 10). Delinquent behaviour was
defined as participating in three or more of the nine behaviours at least once during the past year
(Boak et al., 2018). Isaranuwatchai et al. (2014) analyzed this measure as a binary variable: less
than three behaviours are not indicative of delinquent behaviour (0), three or more behaviours
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are indicative of delinquent behaviour (1). The externalizing problem variable was coded in the
same manner as Isaranuwatchai et al. (2014). All nine behaviours were re-coded into binary
variables: (0) not done it, (1) done it at least once. Then, all nine behaviours were aggregated into
a new variable (called “externalizing problem”) and re-coded (1/2=0, 3-9=1), which means that
three or more of the nine behaviours occurred for participants to be considered as having
externalizing problem.

3.4.7 Supplementary Variables
In this section, variables that were described in this paper but were not part of the objectives
were reported.

3.4.7.1

Age

Age (variable a1) was measured with the following question: “How old are you?”. There were
11 response options, including: “10 years of age or younger” (coded 10), “11 years” (coded 11),
“12 years” (coded 12), “13 years” (coded 13), “14 years” (coded 14), “15 years” (coded 15), “16
years” (coded 16), “17 years” (coded 17), “18 years” (coded 18), “19 years” (coded 19), and “20
years or older” (coded 20).

3.4.7.2

Ethnoracial Background

Ethnoracial background (variable a8) was measured with the following question: “Which of the
following best describes your background? (You may choose more than one category.) Are
you…?”. There were 12 response options, including: “White (for example, British, French,
Italian, Portuguese, Ukrainian, Russian, Israeli”, “Chinese”, “South Asian (for example, East
Indian, Pakistani, Bangladeshi, Sri Lankan”, “Black (African, Caribbean, North American)”,
“Aboriginal (First Nations, Inuit, Métis, non-status Indian)”, “Filipino”, “Latin American,
Central American, South American (for example, Mexican, Brazilian, Chilean, Guatemalan,
Venezuelan, Colombian, Argentinian, Salvadoran, Costa Rican)”, “Southeast Asian (for
example, Vietnamese, Cambodian, Indonesian, Malaysian, Laotian)”, “West Asian or Arab (for
example, Egyptian, Saudi Arabian, Syrian, Iranian, Iraqi, Lebanese, Afghan, Palestinian)”,
“Korean”, “Japanese”, and “Not sure”. Each response option was dichotomized as yes (coded 1)
or no (coded 0).
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3.4.7.3

ADHD Medication

ADHD medication (variable c2a) was measured with the following question: “In the last 12
months, how often did you use medicine to treat ADHD (such as Ritalin, Concerta, Adderall,
Dexedrine) with a prescription or because a doctor told you to take it?”. There were 7 response
options, including: “once a day” (coded 1), “twice a day” (coded 2), “3 times a day” (coded 3),
“4 or more times a day” (coded 4), “used with a prescription, but not in the last 12 months”
(coded 5), “never used with a prescription in lifetime” (coded 6), and “don’t know what this
medicine is” (coded 7). ADHD medication was later dichotomized as taken at least once a day in
the last 12 months (coded 1) or not taken in the last 12 months (coded 2).

3.5 Statistical Analysis
Descriptive statistics were used to summarize the participants in the study. Specifically,
frequencies and proportions for the key study variables, as well as the other descriptive variables
(such as ethnoracial background and age) were reported. Sample size totals (n) were not
weighted in order to provide information on available data; whereas, column proportions with
population estimates were derived from the weighted data in order to satisfy survey data design.
For the first objective, in order to estimate the overall prevalence of ADHD symptoms and the
prevalence for both males and females separately, cross-tabulations were performed. To examine
if prevalence significantly differed between males and females, a proportions test to see if two
subsamples (males vs. females) had the same proportion of those with ADHD symptoms was
run. For the second objective, in order to assess the relationship between ADHD symptoms and
substance use (i.e., alcohol, tobacco cigarettes, cannabis and stimulants), multinomial logistic
regression analyses were conducted. Though the categories created for the dependent variables
were ordered (never, occasional, and regular), with higher values reflecting greater use, ordered
logistic regression could not be used because of violations of the proportional odds assumption.
Instead, the dependent variables were treated as nominal. Preliminary tests to examine if the
proportional odds assumption would hold for an ordinal regression for alcohol use were run.
From the model, the p value was .0004 for the likelihood-ratio test that the proportional odds
assumption holds. Thus, the assumption was rejected as the proportionality of odds assumption
was violated with a significant p value.
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To address the second objective, two sets of models were run. First, the overall relationships
between ADHD symptoms and substance use (alcohol, tobacco cigarettes, cannabis, and
stimulants) in separate models for males and females were assessed. Then, the relationships
between ADHD symptoms and substance use (alcohol, tobacco cigarettes, cannabis, and
stimulants), adjusting for SES and social, emotional, and behavioural problems were assessed; as
in all previous models, these relationships were estimated separately for males and females.
Relative risk ratios with 95% confidence intervals ([CIs] assessed at the p < .05 level of
significance), were generated from these multinomial regression analyses.
Data screening was carried out prior to all statistical analysis. Data screening for non-continuous
variables included analyzing missing data and checking for duplicates. All estimates for both
objectives utilized weighted data. Post-stratification weights were calculated for the sex-by-grade
distributions within each regional stratum separately to restore each regions structure and ensure
that each region is proportionate to the population structure. Furthermore, since the sampling
design employs complex sampling methods and unequal probabilities for selection, all 95% CIs
for relative risk ratios in the regression and descriptive statistics were corrected for
characteristics of the sampling design, using and applying Taylor series methods, specifically
used for analyzing survey data; design-based survey commands allowed for unbiased variances
and point estimates. All data were analyzed using STATA, version 13.0.
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Chapter 4

4

Results

4.1 Description of the Study Sample
A total of 6,923 (42.67% male unweighted; 50.28% male weighted) adolescent Ontarians met the
eligibility criteria (filled out form A-SS and were in grade 9-12) and had no missing data for
variables of interest for this study. All analyses for the two objectives were conducted on this
sample. Ethnoracial background was only used to describe the sample (Table 2); however,
ethnoracial background has a different sample size from all the other variables. All other
variables (alcohol use, tobacco cigarette use, cannabis use, stimulant use, age, SES, internalizing
problem, and externalizing problem) have the same sample size of 6,923. Table 2 provides both
unweighted values (frequency (n)) and weighted values (percentage (%)).
More than half the students (54.97%) reported using alcohol (35.55% occasional level; 19.42%
regular level). For males, 44.04% reported non-use of alcohol, 34.72% reported occasional use of
alcohol, and 21.23% reported regular use of alcohol. For females, 46.02% reported non-use of
alcohol, 36.39% reported occasional use of alcohol, and 17.59% reported regular use of alcohol.
Most respondents (89.72%) reported non-use of tobacco cigarettes. For males, 87.84% reported
non-use of tobacco cigarettes, 8.01% reported occasional use of tobacco cigarettes, and 4.15%
reported regular use of tobacco cigarettes. For females, 91.61% reported non-use of tobacco
cigarettes, 6.01% reported occasional use of tobacco cigarettes, and 2.38% reported regular use
of tobacco cigarettes.
Almost three-quarters of the students (73.92%) reported non-use of cannabis. For males, 72.34%
reported non-use of cannabis, 6.99% reported occasional use of cannabis, and 20.66% reported
regular use of cannabis. For females, 75.50% reported non-use of cannabis, 7.58% reported
occasional use of cannabis, and 16.91% reported regular use of cannabis.
Most of the students (94.77%) reported non-use of stimulants. For males, 93.91% reported nonuse of stimulants, 3.65% reported occasional use of stimulants, and 2.44% reported regular use
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of stimulants. For females, 95.65% reported non-use of stimulants, 1.96% reported occasional
use of stimulants, and 2.40% reported regular use of stimulants.
For the purpose of describing the demographics of this sample, age as well as ethnoracial
background of the sample were recorded in Table 2. The mean age of participants was 15.66 (SD
= 1.26, range 13-20 years), with most participants falling into ages 14-17 (92.54% of the
sample). Mean age for males and females were similar (males = 15.70; females = 15.62). The
majority of the respondents (63.88%) identified their family status (SES) in society as falling in
the “middle”, 20.81% of the respondents identified family status in society as “low”, and 15.32%
of the respondents identified family status in society as “high”. The majority of the respondents
(64.42%) identified their ethnoracial background as “white”. For males, 9.27% reported
internalizing problem and 7.81% reported externalizing problem. For females, 26.23% reported
internalizing problem and 5.19% reported externalizing problem.

59

Table 2: Descriptive Statistics for Study Sample by Sex
Male (n = 2,954)

Female (n = 3,969)

Total (n = 6,923; wn =
669,303)

Frequency

Percentage

Frequency

Percentage

Frequency

Percentage

(n)

(%)

(n)

(%)

(n)

(%)

“No use”

1,297

44.04

1,815

46.02

3,112

45.03

“Occasional

1,074

34.72

1,467

36.39

2,541

35.55

583

21.23

687

17.59

1,270

19.42

2,640

87.84

3,632

91.61

6,272

89.72

199

8.01

239

6.01

438

7.02

115

4.15

98

2.38

213

3.27

2,153

72.34

3,002

75.50

5,155

73.92

205

6.99

311

7.58

516

7.29

596

20.66

656

16.91

1,252

18.80

Substance Use

Alcohol Use

use”
“Regular use”
Tobacco
Cigarette Use
“No use”
“Occasional
use”
“Regular use”
Cannabis Use
“No use”
“Occasional
use”
“Regular use”
Stimulant Use
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“No use”
“Occasional

2,793

93.91

3,796

95.65

6,589

94.77

83

3.65

89

1.96

172

2.81

78

2.44

84

2.40

162

2.42

use”
“Regular use”

Male (n = 2,954)

Female (n = 3,969)

Total (n = 6,923; wn =
669,303)

Demographic

Frequency

Percentage

Frequency

Percentage

Frequency

Percentage

(n)

(%)

(n)

(%)

(n)

(%)

13 years

15

0.37

18

0.29

33

0.34

14 years

581

14.69

874

17.53

1,455

16.10

15 years

733

20.98

1,021

21.26

1,754

21.12

16 years

706

22.61

932

23.07

1,638

22.84

17 years

680

28.11

869

27.65

1,549

27.88

18 years

218

12.13

241

9.34

459

10.74

19 years

19

0.90

12

0.79

31

0.85

Suppress

0.21

Suppress

0.07

Suppress

0.13

493

20.17

759

21.45

1,252

20.81

Variables

Age

20 years or
older
SES
Low
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Middle
High

2,006

64.57

2,638

63.17

4,644

63.88

455

15.26

572

15.38

1,027

15.32

Male (n = 2,948)

Female (n = 3,958)

Total (n = 6,906;
wn = 668,089)

Ethnoracial

Frequency

Percentage

Frequency Percentage Frequency Percentage

Background

(n)

(%)

(n)

(%)

(n)

(%)

White/

2,055

65.51

2,718

63.31

4,733

64.42

893

34.49

1,240

36.69

2,133

35.58

Caucasian
Nonwhite/other
Male (n = 2,954)

Female (n = 3,969)

Total (n = 6,923; wn =
669,303)

Social,

Frequency

Percentage

(n)

(%)

(n)

(%)

(n)

(%)

No

2,683

90.73

2,969

73.77

5,652

82.30

Yes

271

9.27

1,000

26.23

1,271

17.70

Emotional, and

Frequency Percentage Frequency Percentage

Behavioural
Problems
Internalizing
Problem

Externalizing
Problem
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No

2,735

92.19

3,776

94.81

6,511

93.49

Yes

219

7.81

193

5.19

412

6.51

Note. SES: socio-economic status. Percentages are weighted. Data are shown as column %.
n = subpopulation sample size (unweighted); wn = weighted sample size.

4.2 Internal Consistency Reliability of Measures: Cronbach’s
Alphas
The alpha coefficients for the ASRS-v1.1 Screener, the K6 Screener, and the Antisocial
Behaviour Index are presented in Table 3 below. The level of acceptability of an alpha value is
commonly debated, yet it remains common practice to consider alpha reaching the somewhat
arbitrary value of 0.70 as a sufficient measure of internal consistency reliability of an instrument
(Taber, 2018). Therefore, in accordance to common practice, the ASRS-v1.1 Screener, the K6
Screener, and the Antisocial Behaviour Index display internal consistency reliability.
Table 3: Cronbach’s Alphas and Inter-Item Correlations of the ASRS-v1.1 Screener, the
K6 Screener, and the Antisocial Behaviour Index
Measure

Alpha

ASRS-v1.1 Screener
K6 Screener
Antisocial Behaviour Index

0.782
0.887
0.732

Inter-item
correlations
0.374
0.568
0.233

Number of
Items
6
6
9

4.3 Results of Objective 1
Among Ontario adolescents, the prevalence of self-reported ADHD symptoms was 20.22%, 95%
CI [18.52, 22.03], with 16.42%, 95% CI [14.66, 18.34] of males self-reporting ADHD symptoms
and 24.06%, 95% CI [21.79, 26.49] of females self-reporting ADHD symptoms (Table 4).
ADHD symptoms were found to differ significantly by sex (p < .0001), suggesting that females
were significantly more likely than males to report ADHD symptoms.
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Table 4: Prevalence Estimates for ADHD Symptom Screener Status by Sex
Male

Female

Total

(n = 2,954)

(n = 3,969)

(n = 6,923)

% (95% CI)

% (95% CI)

% (95% CI)

No ADHD

83.58 (81.66, 85.34)

75.94 (73.51, 78.21)

79.78 (77.97, 81.48)

(n = 5551)

(n = 2,468)

(n = 3,083)

(n = 5,551)

16.42 (14.66, 18.34)

24.06 (21.79, 26.49)

20.22 (18.52, 22.03)

(n = 486)

(n = 886)

(n = 1,372)

ADHD
(n = 1372)

p value

<.0001

Note. Percentages are weighted; data are shown as column %; n = subpopulation sample size
(unweighted); Pearson chi-square (p value) adjusted for the survey design and transformed into
an F statistic; p value results from cross-tabulations.

4.3.1 Post Hoc Analysis
For the ASRS-v1.1 Screener, four of the six questions capture symptoms of inattention. Post hoc
analyses of the data revealed significant sex differences in response to all questions pertaining to
inattention as well as one of the two questions pertaining to hyperactivity-impulsivity (“often
fidget or squirm with hands or feet”). Two sample t-tests were run for all six symptoms by sex to
examine if there were statistically significant difference in means (higher mean indicated that
more adolescents endorsed “often” or “very often” compared to “never” or “rarely”). Females
were significantly more likely than males to record symptoms of inattention as well as one
symptom of hyperactivity-impulsivity. A post hoc t-test on these scores revealed significant
variation among the two sexes for “often have trouble wrapping up the final details of a project”
(t value of 7.13, p < .001), for “often have difficulty getting things in order when you have a
task” (t value of 3.69, p < .001), for “often have problems remembering appointments” (t value
of 5.43, p < .001), for “task that requires thought, often avoid getting started” (t value of 7.87, p
< .001), and for “often fidget or squirm with hands or feet” (t value of 8.57, p < .001). Whereas,
there was no significant sex difference in the way these adolescents recorded the remaining
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symptom of hyperactivity-impulsivity (“often overly active and compelled to do things”, t value
of -0.84, NS).
Although ADHD medication was not a variable of interest in this study, the variable was used
later in the discussion to help explain these results. Post hoc analyses in this study revealed that
3.23% of males reported taking ADHD medication at least once a day, whereas, 2.20% of
females reported taking ADHD medication at least once a day.

4.4 Results of Objective 2
Table 5 to Table 13 presents the results of the second objective. The results were presented by
substance (alcohol, tobacco cigarettes, cannabis, and stimulants) and by sex. Within each
substance, results for all models (unadjusted model and adjusted model) were combined within a
single table by sex. All the Relative Risk Ratio (RRR) for all models for all substances were
combined within one table by sex (Table 13).
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4.4.1 Alcohol
4.4.1.1

Alcohol Results for Males

Table 5: Weighted Multinomial Logistic Regression for Alcohol Use for Males
Variable

ADHD symptoms

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
1.43
(0.99, 2.06)

SES
Middle vs. Low
High vs. Low
Social,
Emotional, and
Behavioural
Problems
Internalizing
Externalizing

1.40
(0.95, 2.06)

2.14

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
1.22
(0.79, 1.90)

0.95
(0.61, 1.47)

1.05
(0.73, 1.49)
1.20
(0.78, 1.85)

1.43
(0.88, 2.30)
2.58
(1.47, 4.54)**

0.50
3.04*

1.31
(0.69, 2.48)
2.67
(1.38, 5.19)**

1.24
0.53
(0.78, 1.99)
9.88
21.14***
(4.94, 19.78)***

Note. The reference group for the outcome is non-use of alcohol. OU: Occasional Use. RU:
Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data are
from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada. Results
are weighted and adjusted for survey design. Overall F statistics obtained through testparm.
“Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 5 presents the results to address the second objective: to assess the overall relationship
between ADHD symptoms and alcohol use for males. The F statistic from the unadjusted
regression model indicates that ADHD symptoms were not statistically significantly correlated
with alcohol use for males.
Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and alcohol use while controlling for SES and social, emotional, and behavioural
problems among males. In Model 2 (objective 2, part b), after the addition of both SES and
social, emotional, and behavioural problems, the relationship between ADHD symptoms and
alcohol use remained statistically non-significant. ADHD symptoms were not significantly
related to alcohol use in either model. The only difference between both models is that the
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addition of covariates caused the RRR of ADHD symptoms to become closer to the null (null =
1).

4.4.1.2

Alcohol Results for Females

Table 6: Weighted Multinomial Logistic Regression for Alcohol Use for Females
Variable

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test

1.38
1.79
6.18**
ADHD
(1.12,
1.69)**
(1.19,
2.67)**
symptoms
SES
Middle vs. Low

High vs. Low
Social,
Emotional, and
Behavioural
Problems
Internalizing
Externalizing

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
1.15
(0.95, 1.41)

1.44
(0.92, 2.24)

1.17
(0.91, 1.51)
0.94
(0.54, 1.62)

1.34
(0.95, 1.89)
1.33
(0.90, 1.94)

2.03
0.97

1.33
1.18
2.26
(1.01, 1.75)*
(0.84, 1.67)
5.34
15.35
31.82***
(2.44, 11.68)*** (7.69, 30.65)***

Note. The reference group for the outcome is non-use of alcohol. OU: Occasional Use. RU:
Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data are
from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada. Results
are weighted and adjusted for survey design. Overall F statistics obtained through testparm.
“Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 6 presents the results to address the second objective: to assess the overall relationship
between ADHD symptoms and alcohol use for females. The F statistic from the unadjusted
regression model for alcohol use for females indicates that ADHD symptoms were statistically
significantly correlated with alcohol use. On average, females with ADHD symptoms had a 1.38,
[95% CI: 1.12, 1.69] increased risk of occasionally using alcohol (relative to non-drinkers),
compared to females without ADHD symptoms. Similarly, on average, females with ADHD
symptoms had a 1.79, [95% CI: 1.19, 2.67] increased risk of regularly using alcohol (relative to
non-drinkers), compared to females without ADHD symptoms.
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Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and alcohol use, while accounting for SES and social, emotional, and behavioural
problems. With the addition of covariates in Model 2, the relationship between ADHD
symptoms and alcohol use for females became non-significant compared to Model 1.

4.4.2 Tobacco Cigarettes
4.4.2.1

Tobacco Cigarette Results for Males

Table 7: Weighted Multinomial Logistic Regression of Tobacco Cigarettes Use for Males
Variable

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test

1.15
3.49
ADHD
(0.61,
2.17)
(1.57,
7.74)**
symptoms
SES
Middle vs.
Low
High vs. Low

Social,
Emotional, and
Behavioural
Problems
Internalizing
Externalizing

5.44**

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
0.76
(0.34, 1.68)

1.52
(0.70, 3.33)

0.85
0.93

1.03
(0.61, 1.73)
0.60
(0.30, 1.22)

0.63
(0.31, 1.27)
0.63
(0.21, 1.87)

1.71
2.33
3.88*
(0.87, 3.37)
(1.05, 5.18)*
4.03
8.31
26.19***
(2.22, 7.30)*** (4.09, 16.88)***

Note. The reference group for the outcome is non-use of tobacco cigarettes. OU: Occasional Use.
RU: Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data
are from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada.
Results are weighted and adjusted for survey design. Overall F statistics obtained through
testparm. “Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 7 presents the results to address the second objective: assess the overall relationship
between ADHD symptoms and substance use (tobacco cigarettes), for males. The F statistic from
the unadjusted regression model for males indicates that ADHD symptoms were statistically
significantly correlated with tobacco cigarette use. However, not all across-group differences
were statistically significant. On average, males with ADHD symptoms had a 3.49 [95% CI:
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1.57, 7.74] increased risk of regularly using tobacco cigarettes (relative to those who did not use
tobacco cigarettes), compared to males without ADHD symptoms.
Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and substance use (tobacco cigarettes) while accounting for SES and social,
emotional, and behavioural problems, for males. So, with the addition of covariates in Model 2,
the relationship between ADHD symptoms and tobacco cigarette use for males became nonsignificant compared to Model 1.

4.4.2.2

Tobacco Cigarette Results for Females

Table 8: Weighted Multinomial Logistic Regression of Tobacco Cigarettes Use for Females
Variable

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test

2.72
3.91
26.20***
2.01
ADHD
(1.87, 3.98)*** (1.92, 7.97)***
(1.26, 3.22)**
symptoms
SES
1.44
Middle vs.
(0.84,
2.45)
Low
1.69
High vs. Low
(1.01, 2.83)*

Social,
Emotional, and
Behavioural
Problems
Internalizing
Externalizing

1.51
(0.72, 3.17)

5.95**
2.03

0.53
(0.23, 1.23)
0.68
(0.22, 2.11)

1.54
5.26
14.57***
(0.95, 2.50) (2.61, 10.57)***
5.73
11.36
24.72***
(3.13, 10.49)*** (4.75, 27.13)***

Note. The reference group for the outcome is non-use of tobacco cigarettes. OU: Occasional Use.
RU: Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data
are from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada.
Results are weighted and adjusted for survey design. Overall F statistics obtained through
testparm. “Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 8 presents the results to address the second objective: assess the overall relationship
between ADHD symptoms and tobacco cigarettes for females. The F statistic from the
unadjusted regression model for tobacco cigarette use for females indicates that ADHD
symptoms were statistically significantly correlated with tobacco cigarette use for females. On
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average, females with ADHD symptoms had a 2.72 [95% CI: 1.87, 3.98] increased risk of
occasionally using tobacco cigarettes (relative to those who did not use tobacco cigarettes),
compared to females without ADHD symptoms. Similarly, on average, females with ADHD
symptoms had a 3.91 [95% CI: 1.92, 7.97] increased risk of regularly using tobacco cigarettes
(relative to those who did not use tobacco cigarettes), compared to females without ADHD
symptoms.
Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and substance use (tobacco cigarettes) while accounting for SES and social,
emotional, and behavioural problems, for females. In Model 2 (objective 2, part b), after the
addition of both SES and social, emotional, and behavioural problems, the overall relationship
between ADHD symptoms and tobacco cigarette use for females, remained statistically
significant. The adjusted model with SES and social, emotional, and behavioural problems
indicates that ADHD symptoms were statistically significantly correlated with tobacco cigarette
use for females; however, not all across-group differences remained statistically significant.
In summary, ADHD symptoms were statistically significantly related to tobacco cigarette use in
both the overall unadjusted and overall adjusted models. The only difference is that the addition
of covariates caused the RRR of ADHD symptoms to become closer to the null (null = 1) from
Model 1 to Model 2.
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4.4.3 Cannabis
4.4.3.1

Cannabis Results for Males

Table 9: Weighted Multinomial Logistic Regression of Cannabis Use for Males
Variable

ADHD symptoms

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
0.92
(0.52, 1.60)

1.52
(0.96, 2.40)

SES
Middle vs. Low
High vs. Low
Social, Emotional,
and Behavioural
Problems
Internalizing
Externalizing

1.63

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
0.70
(0.40, 1.25)

0.91
(0.57, 1.44)

1.04
(0.48, 2.25)
0.97
(0.41, 2.32)

0.91
(0.63, 1.30)
0.82
(0.43, 1.55)

0.77
0.11

1.51
1.32
0.89
(0.73, 3.09)
(0.81, 2.15)
3.55
9.91
45.04***
(1.49, 8.43)** (6.15, 15.98)***

Note. The reference group for the outcome is non-use of cannabis. OU: Occasional Use. RU:
Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data are
from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada. Results
are weighted and adjusted for survey design. Overall F statistics obtained through testparm.
“Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 9 presents the results to address the second objective: assess the relationship between
ADHD symptoms and substance use (cannabis), for males. The results of the unadjusted
regression model for males indicates that ADHD symptoms were not statistically significantly
correlated with cannabis use for males.
Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and substance use (cannabis) while accounting for SES and social, emotional, and
behavioural problems, for males. In Model 2 (objective 2, part b), after the addition of both SES
and social, emotional, and behavioural problems, the relationship between ADHD symptoms and
cannabis use remained statistically non-significant for males, in comparison to the unadjusted
model. The adjusted model for males with SES and social, emotional, and behavioural problems
indicates that ADHD symptoms were not statistically significantly correlated with cannabis use.
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ADHD symptoms were not statistically significantly related to cannabis use in either model. The
only difference is that the addition of covariates caused the RRR of ADHD symptoms to become
closer to the null (null = 1) for regular cannabis use and further from the null for occasional
cannabis use; however, the covariates did not significantly change the relationship of ADHD
symptoms to cannabis use for males from Model 1 to Model 2.

4.4.3.2

Cannabis Results for Females

Table 10: Weighted Multinomial Logistic Regression of Cannabis Use for Females
Variable

ADHD symptoms

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
1.58
2.21
9.69***
(0.99, 2.53) (1.55, 3.15)***

SES
Middle vs. Low
High vs. Low
Social, Emotional,
and Behavioural
Problems
Internalizing
Externalizing

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
1.63
(1.01, 2.62)*

1.49
(1.10, 2.00)*

1.18
(0.62, 2.27)
1.14
(0.68, 1.90)

1.17
(0.74, 1.86)
1.17
(0.64, 2.16)

4.84**
0.14

0.84
1.67
6.74**
(0.51, 1.39)
(1.23, 2.26)**
4.24
14.92
50.42***
(1.93, 9.31)*** (8.73, 25.51)***

Note. The reference group for the outcome is non-use of cannabis. OU: Occasional Use. RU:
Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data are
from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada. Results
are weighted and adjusted for survey design. Overall F statistics obtained through testparm.
“Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 10 presents the results to address the second objective: assess the overall relationship
between ADHD symptoms and substance use (cannabis), for females. The results of the
unadjusted regression model (F statistic) indicates that ADHD symptoms were statistically
significantly correlated with cannabis use for females; however not all across-group differences
were statistically significant. On average, females with symptoms of ADHD had a 2.21 [1.55,
3.15] increased risk of regularly using cannabis (relative to those who did not use cannabis),
compared to females without ADHD symptoms.
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Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and substance use (cannabis) while accounting for SES and social, emotional, and
behavioural problems, for females. In Model 2 (objective 2, part b), after the addition of both
SES and social, emotional, and behavioural problems, the relationship between ADHD
symptoms and cannabis use for females, remained statistically significant, when comparing
results to the unadjusted model. The adjusted model with SES and social, emotional, and
behavioural problems indicates that ADHD symptoms were statistically significantly correlated
with cannabis use for females. On average, females with ADHD symptoms were at 1.63 [95%
CI: 1.01, 2.62] times the risk of occasionally using cannabis (relative to those who did not use
cannabis) compared to females without ADHD symptoms, when SES and social, emotional, and
behavioural problems were adjusted. On average, females with ADHD symptoms were at 1.49
[95% CI: 1.10, 2.00] times the risk of regularly using cannabis (relative to those who did not use
cannabis) compared to females with ADHD symptoms, when SES and social, emotional, and
behavioural problems were adjusted.
ADHD symptoms were statistically significantly related to cannabis use in both models, for
females. The only difference is that the addition of covariates caused the RRR of ADHD
symptoms to become closer to the null (null = 1) for regular cannabis use and further away from
the null for occasional cannabis use, from Model 1 to Model 2.
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4.4.4 Stimulants
4.4.4.1

Stimulants Results for Males

Table 11: Weighted Multinomial Logistic Regression of Stimulant Use for Males
Variable

ADHD symptoms

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
3.39
2.29
3.88*
(1.04, 11.03)* (1.03, 5.13)*

SES
Middle vs. Low
High vs. Low
Social, Emotional,
and Behavioural
Problems
Internalizing
Externalizing

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
1.81
(0.78, 4.20)

1.50
(0.63, 3.60)

1.06
(0.46, 2.42)
1.05
(0.29, 3.86)

0.76
(0.33, 1.75)
0.78
(0.20, 3.01)

1.23
0.13

1.40
0.43
1.96
(0.73, 2.67)
(0.16, 1.19)
9.09
13.25
41.86***
(4.30, 19.22)*** (6.22, 28.24)***

Note. The reference group for the outcome is non-use of stimulants. OU: Occasional Use. RU:
Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data are
from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada. Results
are weighted and adjusted for survey design. Overall F statistics obtained through testparm.
“Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 11 presents the results to address the second objective: assess the overall relationship
between ADHD symptoms and substance use (stimulants), for males. The F statistic from the
unadjusted regression model for males indicates that ADHD symptoms were statistically
significantly correlated with stimulant use for males. On average, males with ADHD symptoms
had a 3.39 [95% CI: 1.04, 11.03] increased risk of occasionally using stimulants (relative to
those who did not use stimulants), compared to males without ADHD symptoms. Similarly, on
average, males with ADHD symptoms had a 2.29 [95% CI: 1.03, 5.13] increased risk of
regularly using stimulants (relative to those who did not use stimulants), compared to males
without ADHD symptoms.
Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and substance use (stimulants) while accounting for SES and social, emotional, and
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behavioural problems, for males. With the addition of covariates in Model 2, the relationship
between ADHD symptoms and stimulants use for males became non-significant compared to
Model 1.

4.4.4.2

Stimulants Results for Females

Table 12: Weighted Multinomial Logistic Regression of Stimulant Use for Females
Variable

ADHD symptoms

Model 1: unadjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
2.40
3.22
10.50***
(1.27, 4.55)** (1.51, 6.85)**

SES
Middle vs. Low
High vs. Low
Social, Emotional,
and Behavioural
Problems
Internalizing
Externalizing

Model 2: adjusted model
RRR (95% CI)
Wald
Test
OU
RU
F Test
1.39
(0.60, 3.24)

1.25
(0.55, 2.82)

0.43
0.08

0.91
(0.40, 2.07)
0.89
(0.29, 2.75)

1.08
(0.42, 2.73)
1.29
(0.43, 3.85)

1.44
4.29
7.74***
(0.68, 3.06)
(2.07, 8.89)***
14.57
14.25
48.93***
(7.06, 30.05)*** (6.93, 29.31)***

Note. The reference group for the outcome is non-use of stimulants. OU: Occasional Use. RU:
Regular Use. Cells indicate relative risk ratio with 95% confidence interval in brackets. Data are
from the 2015 and 2017 Ontario Student Drug Use and Health Survey, Ontario, Canada. Results
are weighted and adjusted for survey design. Overall F statistics obtained through testparm.
“Low” is the reference category for SES. *p < .05. **p < .01. ***p <.001.
Table 12 presents the results to address the second objective: assess the overall relationship
between ADHD symptoms and substance use (stimulants), for females. The F statistic from the
unadjusted regression model for females indicates that ADHD symptoms were statistically
significantly correlated with stimulant use for females. On average, females with ADHD
symptoms had a 2.40 [95% CI: 1.27, 4.55] increased risk of occasionally using stimulants
(relative to those who did not use stimulants), compared to females without ADHD symptoms.
Similarly, on average, females with ADHD symptoms had a 3.22 [95% CI: 1.51, 6.85] increased
risk of regularly using stimulants (relative to those who did not use stimulants), compared to
females without ADHD symptoms.

75

Results from Model 2 address the following objective: to assess the relationship between ADHD
symptoms and substance use (stimulants) while accounting for SES and social, emotional, and
behavioural problems, for females. With the addition of covariates in Model 2, the relationship
between ADHD symptoms and stimulant use for females became non-significant compared to
Model 1.

4.4.5 Summary of Results for All Substances
Table 13: Weighted Multinomial Logistic Regression Relative Risk Ratio Summary of
Substance Use by Sex
OU
ADHD symptoms – Model
1: unadjusted model
ADHD symptoms – Model
2: adjusted model

Male - Alcohol
RU
F Test

1.43

1.4

2.14

1.38**

1.79**

6.18**

1.22

0.95

0.5

1.15

1.44

2.03

Male – Tobacco Cigarettes
OU
RU
F Test
ADHD symptoms – Model
1: unadjusted model
ADHD symptoms – Model
2: adjusted model
ADHD symptoms – Model
1: unadjusted model
ADHD symptoms – Model
2: adjusted model

Female – Tobacco Cigarettes
OU
RU
F Test

1.15

3.49**

5.44**

2.72***

3.91***

26.20***

0.76

1.52

0.85

2.01**

1.51

5.95**

Male - Cannabis
OU
RU
F Test

Female - Cannabis
OU
RU
F Test

0.92

1.52

1.63

1.58

2.21***

9.69***

0.7

0.91

0.77

1.63*

1.49*

4.84**

OU
ADHD symptoms – Model
1: unadjusted model
ADHD symptoms – Model
2: adjusted model

Female - Alcohol
OU
RU
F Test

Male - Stimulants
RU
F Test

Female - Stimulants
OU
RU
F Test

3.39*

2.29*

3.88*

2.40**

3.22**

10.50***

1.81

1.5

1.23

1.39

1.25

0.43

Note. The reference group for the outcome is non-use of substance. OC: Occasional Use. R:
Regular Use. Data are from the 2015 and 2017 Ontario Student Drug Use and Health Survey,
Ontario, Canada. Results are weighted and adjusted for survey design. Overall F statistics
obtained through testparm. *p < .05. **p < .01. ***p <.001.
All RRR accompanied with the level of significance can be found in Table 13. Table 13 is
sectioned by sex (results for males on the left of the table), and substance use is displayed by
rows from alcohol to stimulants. This table will ease the process of comparing substance to
substance in the discussion portion of this thesis.
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Chapter 5

5

Discussion

The purpose of this population-based study was to estimate the prevalence of self-reported
ADHD symptoms by sex and to assess the relationship between ADHD symptoms and substance
use by sex.

5.1 Prevalence of ADHD Symptoms Among Ontario Youth
The overall prevalence of self-reported ADHD symptoms in Ontario among youth, using the
ASRS-v1.1 Screener was found to be 20.22%. As hypothesized, this estimate is much higher
than in previous Canadian studies that have used actual ADHD diagnoses which ranged from
1.5% (Brownell & Yogendran, 2001) to 10.49% (Georgiades et al., 2019). In general, studies
that used a survey symptom checklist to measure ADHD, including this study, produced larger
prevalence statistics compared to studies that used administrative medical records. In addition,
symptom checklists are possibly more inclusive whereas actual diagnoses by physicians or
psychologists are more exclusive as clinicians try to identify other disorders that could account
for the symptoms and assess functional impairment in two or more domains that are not typically
captured in survey symptom checklists. In fact, the current estimate of 20.22% is in accordance
with the estimates of Green et al. (2019) (study from the United States) and Sonnby et al. (2011)
(study from Sweden) of 19.6% and 20.90%, respectively. Both Green et al. (2019) and Sonnby et
al. (2011) used the ASRS-v1.1 Screener with adolescents to estimate the prevalence of selfreported ADHD symptoms.
Furthermore, females self-reported ADHD symptoms significantly more than males (24.06% vs.
16.42%, respectively). Studies using the same ASRS measure that was used in this study found
that more females self-reported symptoms of ADHD than males (Madruga et al., 2012;
Polanczyk et al., 2010; Sonnby et al., 2011). For example, Sonnby et al. (2011) found that 18.4%
of males self-reported ADHD symptoms and 23.5% of females self-reported ADHD symptoms.
It is possible that the ASRS-v1.1 Screener is capturing more than ADHD, particularly since the
post-hoc analysis conducted for this study indicates that of this entire sample, 3.23% of males
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and 2.20% of females reported taking ADHD medication at least once a day in this current study.
The number of participants who actually have ADHD is likely to be higher than the percentage
who take ADHD medication because not all of those with ADHD take ADHD medication. Some
parents are reluctant to have their children take medication due to medication side effects
(Cascade, Kalali, & Wigal, 2010; Toomey, Sox, Rusinak, & Finkelstein, 2012), medication
ineffectiveness, and the availability of other therapies besides medication (Barkley, 2004;
Zylowska et al., 2008). Therapies besides medication include behavioural parent training,
behavioural classroom management, behavioural peer interventions, and organization training
programs; unfortunately, there is a significant gap between research and practice, such that these
treatments are often not implemented in community and school settings (DuPaul, Evans,
Mautone, Owens, & Power, 2019). Furthermore, there is evidence that it is more effective to
begin with behavioural treatment and add medication as a secondary treatment to initial
behaviour modification, compared to beginning with medication and adding behavioural
treatment later (Pelham et al., 2016). That said, the medication use estimates from this survey are
more congruent with prevalence estimates of ADHD from studies using measures of clinical
diagnosis, suggesting that the ASRS-v1.1 Screener may be capturing a broader range of
symptoms and issues in addition to ADHD symptoms.
The prevalence of one in five Ontario high school students reporting symptoms of ADHD may
be reflective of overall trends in mental health. In general, youth are experiencing more mental
health issues pertaining to internalizing problems; there has been an overall increasing trend of
adolescent mental health symptoms globally since the 1980s, especially an increase of
internalizing symptoms in females (Blomqvist, Henje Blom, Hägglöf, & Hammarström, 2019).
Between 1980/81 and 2004/05, there was an increasing prevalence of self-reported anxiety; the
increase was particularly large in young females between ages 16-23 years (Calling, Midlöv,
Johansson, Sundquist, & Sundquist, 2017). Blomqvist et al. (2019) found that symptoms of
anxiety and depression and functional somatic symptoms increased among males and females
from 1981 until 2014 (p < .001 for all subscales), and the increase of these symptoms were
higher among females. Conversely, conduct problems were significantly higher in males in 1981
and decreased over time so that in 2014, there was no longer a significant difference between
males and females regarding conduct problems (p = .286) (Blomqvist et al., 2019). Conduct
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disorder decreased from 7.2% to 2.5% while emotional disorder increased from 9.2% to 13.2%
between 1983 and 2014 in Ontario youth (Comeau et al., 2019).
The increase of mental health issues may be a result of a number of cultural trends (Twenge,
Cooper, Joiner, Duffy, & Binau, 2019). Twenge et al. (2019) analyzed data from the National
Survey on Drug Use and Health, examining survey responses from more than 200,000
adolescents age 12-17 from 2005-2017 and about 400,000 adults age 18 and over from 20082017. The percentage of young Americans experiencing certain types of mental health disorders
has risen significantly over the past decade, with no corresponding increase in older adults
(Twenge et al., 2019). These cultural trends included an increased use of electronic
communication and digital media which may have changed modes of social interaction enough
to affect mood disorders (Twenge et al., 2019). Furthermore, youth are not sleeping as much as
they did in previous generations, and this could be because digital media can interfere with sleep
(e.g., staying up late on phones, using them in the middle of the night) (Twenge et al., 2019).
Given that the increase in mental health issues was sharpest after 2011, it is unlikely to be due to
genetics or economic problems, but instead how adolescents choose to spend their leisure time
(Twenge et al., 2019). Lastly, this spike in mental health issues is happening particularly to
female adolescents (Twenge et al., 2019), which could be why the females that respond to the
ASRS measure have been self-reporting more ADHD symptoms than males.
To add to reasons why females may have self-reported significantly more ADHD symptoms than
males, females are more ready to acknowledge and disclose discomfort than males (Barsky,
Peekna, & Borus, 2001; Hill & Stull, 1987; Ubando, 2016). This could be part of the genderbased socializing process in society. Masculinity is a risk factor for male vulnerability (e.g.,
emotional inexpressiveness, reluctance to seek help) (Möller-Leimkühler, 2003); however,
females are more sensitized to bodily sensation and discomfort leading to heightened selfscrutiny which could increase symptom reporting. In this current study, females were
significantly more likely than males to self-report symptoms of inattention as well as one
symptom of hyperactivity-impulsivity. A post hoc t-test on these scores revealed significant
variation among the two sexes for “often have trouble wrapping up the final details of a project”
(t value of 7.13, p < .001), for “often have difficulty getting things in order when you have a
task” (t value of 3.69, p < .001), for “often have problems remembering appointments” (t value
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of 5.43, p < .001), for “task that requires thought, often avoid getting started” (t value of 7.87, p
< .001). Furthermore, females were significantly more likely than males to record “often fidget
or squirm with hands or feet” (t value of 8.57, p < .001); whereas, there was no significant sex
difference in the way these adolescents recorded the remaining symptom of hyperactivityimpulsivity (“often overly active and compelled to do things”, t value of -0.84, NS). This sex
difference could be attributed to differential reporting between the sexes.
Lastly, one important finding from the 2014 OCHS is that prevalence largely depends on
whether diagnoses are based on youth versus parent report (Georgiades et al., 2019). The overall
prevalence of any symptoms of mental health was 18.2% for youth (12-17 years) based on parent
reports and 21.8% based on youth reports. Among youth, the overall prevalence of any disorder
was higher for females compared to males based on the youth reports (25.4% versus 18.5%) but
generally higher in males compared to females based on the parent reports (20.5% versus
15.8%). Furthermore, the higher prevalence of any disorder in females identified by youth
compared to adults was attributable to major depressive episode (10.1% versus 5.1%) and
generalized anxiety (13.3% versus 6.3%), while the higher prevalence of any disorder in males
identified by parents compared to youth was largely attributable to ADHD (7.5% versus 2.7%).
Although prevalence estimates were similar for males and females for mood and anxiety
disorders based on parent reports, youth reports revealed rates that were 2 to 3 times higher for
females compared to males.

5.2 ADHD Symptoms and Substance Use
The use of both unadjusted models and adjusted models provided a better understanding of the
association between ADHD symptoms and substance use. The unadjusted models suggest that
ADHD symptoms are related to most types of substance use (tobacco cigarette use and stimulant
use in males, and alcohol use, tobacco cigarette use, cannabis use, and stimulant use in females).
Once adjusting for covariates, it is clearer that internalizing and externalizing problem are highly
related to substance use (while SES is only highly related to regular alcohol use in males), and
ADHD symptoms are only related to tobacco cigarette use and cannabis use in females, once
accounting for covariates.
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5.2.1 ADHD Symptoms and Alcohol Use
Consistent with some literature (Flory et al., 2003; Galéra et al., 2008; Upadhyaya & Carpenter,
2008), once controlling for SES and social, emotional, and behavioural problems, there was no
relationship between ADHD symptoms and alcohol use for both males and females. However,
these findings are dissimilar to other research that found that ADHD symptoms decreased the
risk of alcohol use (Fergusson et al., 2007) and that risk of alcohol use may be more apparent in
females with ADHD symptoms compared to females without ADHD symptoms (Elkins et al.,
2018; Sihvola et al., 2011).
Age of participants could also have affected these results because historically, those who are
older are more likely to use or have used alcohol (Boak, Hamilton, Adlaf, & Mann, 2017). For
example, Flory et al. (2003) studied participants in 6th-10th grade and did not find a relationship
between ADHD symptoms and alcohol use whereas Fergusson et al. (2007) studied participants
at age 16, 18, 21, and 25 and did find a relationship between ADHD symptoms and alcohol use.
However, both Elkins et al. (2018) and Sihvola et al. (2011) examined a similar age group to the
current study (participants aged 17, participants aged 14 and 17, respectively) and found that
ADHD symptoms were related to alcohol use.
Perhaps the association between ADHD symptoms and alcohol use is more evident for those
who drink more frequently than occasional drinkers. Although for this study, both “occasional”
and “regular” labels to categorize level of drinking were used, this definition of regular drinking
included drinking “2 or 3 times a month”, “once a week”, “2 or 3 times a week”, “4 or 5 times a
week”, and “almost every day- 6 or 7 times a week”. This definition of regular drinking is very
broad when compared to studies that used a measurement of weekly/daily drinking (Elkins et al.,
2018; Sihvola et al., 2011). Elkins et al. (2018) and Sihvola et al. (2011) used the most
comprehensive measure of alcohol use when compared to studies that did not find a relationship
between ADHD symptoms and alcohol use (Flory et al., 2003; Galéra et al., 2008; Upadhyaya &
Carpenter, 2008). Flory et al. (2003) examined past month use of alcohol. Galéra et al. (2008)
examined binge use (five or more drinks in a row at least twice a week in the last two weeks) and
regular drinker (10 times in last 30 days). Upadhyaya and Carpenter (2008) examined past year
alcohol use (response options included: once per year, six times per year, once per month, twice
per month, once per week, three times per week, five times per week, every day). Therefore,
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researchers who focused more on weekly/daily drinking (participants that drink more) found an
association between ADHD symptoms and alcohol use (Elkins et al., 2018; Sihvola et al., 2011).

5.2.2 ADHD Symptoms and Tobacco Cigarette Use
As hypothesized, ADHD symptoms were statistically significantly related to tobacco cigarette
use in females. Consistent with Galéra et al. (2005), females with ADHD symptoms had a
significantly increased risk of using tobacco cigarettes than females without ADHD symptoms.
Galéra et al. (2005) found that ADHD symptoms contributed independently to subsequent daily
smoking (OR = 1.98, p = .04) only for females. Reasons for this difference could be that females
experience greater social and academic consequences related to inattention symptoms. On
average, females are more academically motivated than males, so females with inattention
symptoms violate this common gender role thereby further isolating them from peers) (Elkins et
al., 2011) leading them to use tobacco cigarettes as a way to cope with these consequences. For
example, it has been suggested that females with ADHD symptoms may have more difficulty in
peer relationships than all other comparison groups (including females without ADHD
symptoms, males with ADHD symptoms, and males without ADHD symptoms) (Mikami &
Hinshaw, 2003). One population study of 11-year-olds found that females with ADHD
symptoms, especially the inattentive subtype, did more poorly with school and peer relationships
than females without ADHD symptoms as well as males with and without ADHD symptoms
(Elkins et al., 2011). Elkins et al. (2011) found that youth with ADHD symptoms experienced
lower popularity and self-concept, fewer positive peers, and increased deviant peers. Females
with ADHD symptoms were less popular and more likely to be bullied than females without
ADHD, whereas males with ADHD symptoms were not. Specifically, 50% of females with
inattention symptoms reported being bullied compared to 29% of males with inattention
symptoms. Perhaps since females are more academically motivated than males overall, females
with inattention symptoms are in violation of a common gender role expectation and are thereby
subjected to greater social stigma (Elkins et al., 2011). Furthermore, inattention may impair the
ability to be attuned to subtle social cues and norms, and females may be expected to be aware of
and responsive to these cues. Peer adjustment may be of heightened significance at this age,
when adaptive peer relationships are central for competency (Masten & Curtis, 2000). The social
isolation experienced by many females with ADHD symptoms may lead them to use tobacco
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cigarettes as a way to cope. It is speculated that for these reasons, ADHD symptoms were
statistically significantly related to tobacco cigarette use in females, only.

5.2.3 ADHD Symptoms and Cannabis Use
Similar to previous research (Elkins et al., 2018; Fergusson et al., 2007; Upadhyaya & Carpenter,
2008), the results from this study indicated that ADHD symptoms were significantly related to
cannabis use; however, unlike some previous research (Fergusson et al., 2007; Upadhyaya &
Carpenter, 2008), this current study found that this relationship only exists among females with
ADHD symptoms and not males with ADHD symptoms. Elkins et al. (2018) also found that the
risk of cannabis use was more apparent in females with ADHD symptoms compared to females
without ADHD symptoms; each hyperactive-impulsive symptom was associated with a 40%
increase in odds for females (19% for males) of progressing in cannabis frequency (e.g., weekly
to daily). However, Elkins et al. (2018) found that ADHD symptoms still significantly predicted
cannabis frequency for males. Similar to the risk of tobacco cigarette use in females, this current
study found the risk of cannabis use only existed for females with ADHD symptoms, but not for
males with ADHD symptoms. Again, this could be explained by the greater social and academic
consequences that females experience from symptoms of inattention (Elkins et al., 2011) which
could lead them to use cannabis as a way to cope with these consequences.

5.2.4 ADHD Symptoms and Stimulant Use
Unlike previous research (Galéra et al., 2013), the current study did not find a significant
relationship between ADHD symptoms and stimulant use after controlling for SES, internalizing
problem, and externalizing problem. This could be attributed to differences in stimulant use
measure. Galéra et al. (2013) measured only lifetime cocaine use whereas this study measured
the frequency of stimulant use, including cocaine, crack-cocaine, methamphetamine, and ecstasy.
Since Galéra et al. (2005) found a significant relationship between ADHD symptoms and daily
tobacco cigarette use but no relationship between ADHD symptoms and lifetime smoking, one
would hypothesize that the use of lifetime measurement dilutes any association between ADHD
symptoms and lifetime cocaine use. However, perhaps this conclusion regarding lifetime
measurement cannot be used for substances that are not as commonly used as tobacco cigarettes;
substance use experimentation can be regarded as a normative experience rather than as deviant
behaviour for tobacco cigarette use, but this may not extend to cocaine use. However, with such
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limited number of studies to use as comparisons and such different methods of measurement, it is
understandable that the results obtained from this study are different.

5.2.5 Comparison Across Sexes
Interestingly, there was a significant relationship between ADHD symptoms and tobacco
cigarette use and cannabis use for females even after controlling for covariates, but not for males.
These results stand in contrast to earlier findings that males with ADHD have a higher frequency
of substance use than females with ADHD (Galéra et al., 2008); yet they corroborate earlier
work by Elkins et al. (2018), Galéra et al. (2005), and Sihvola et al. (2011), which indicate that
females with ADHD symptoms may share a similarly increased risk of substance use compared
to their male counterparts.

5.3 Strengths and Limitations
Population-based studies have both strengths and limitations. Population-based studies are the
best design to examine the relationship between health-related characteristics and other variables
of interest as they exist in a population at one particular time. It is the best study design for
quantifying prevalence and risk factors. Although population-based studies cannot capture all
members of the population (except for census studies), it is a technique that can capture more
cases compared to other types of study designs that include a smaller sample size or rely on
clinical diagnosis for case identification. Lastly, poststratification weights can be applied to
population data to restore the population gender distribution according to grade. Applying
weights addressed the issue of younger female overrepresentation and older male
underrepresentation in the OSDUHS.
However, the current results must be interpreted in light of the limitations related to crosssectional data, measures used (scales and questions included and self-report nature of the survey
without corroborating or objective measures), and generalizability of the results to the whole
population.
Due to the cross-sectional nature of this study design, the ability to make definitive conclusions
about temporality or directionality between the variables in this study were not possible. These
findings of associations were correlational and do not imply causation. Therefore, more
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longitudinal studies are needed to explore the direction of the relationship between self-reported
ADHD symptoms and substance use, specifically tobacco cigarette, and cannabis use in females.
Measures used in this study should also be interpreted cautiously. This study examined
prevalence and correlates utilizing screening tools such as the ASRS-v1.1 Screener and K6
Screener instead of psychiatric assessments. It is difficult to ascertain whether ASRS-v1.1
Screener is in fact capturing ADHD symptomatology rather than a broad-spectrum of
psychological symptoms. Although the psychometrics of the ASRS-v1.1 Screener in this study
are strong, these screeners were not intended to provide diagnosis of disorders (Caci, Morin, &
Tran, 2014). Therefore, the use of screening measures such as the ASRS-v1.1 Screener, the K6
Screener, and the Antisocial Behaviour Index, as well as all the single question substance use
frequency measures, as opposed to full-length assessments and clinical diagnoses, is a
methodological limitation.
The OSDUHS data collection method relied solely on self-report which could lead to social
desirability bias, which is the tendency for respondents to answer questions in a fashion that will
be viewed favourably by others (Krosnick, 1999). However, reviews of self-report methods for
substance use suggest that although surveys typically underestimate true usage, surveys are
deemed the best available method to estimate such behaviour (Harrison, Haaga, & Richards,
1993).
Additionally, self-report often leads to a large amount of missing data (Salgado, Azevedo,
Proença, & Vieira, 2016). In surveys, missing data can be caused by many reasons: 1)
respondents may refuse to answer a question because of privacy issues; 2) respondents may not
understand the question posed; 3) respondents may lose interest in the completion of the survey;
4) subject matter may be private or illicit (such as frequency of stimulant use) (SPSS, n.d.). In
this study, about 10% of the data were missing, which is a limitation, as imputation methods
were not used to correct for this issue. Additionally, recall bias may lead to differential exposure
misclassification, so an objective source of information is often better (i.e., registry) than selfreported measures. Furthermore, there may be differential self-reporting based on sex. As stated
before, females are historically more ready to acknowledge and disclose discomfort compared to
males (Barsky et al., 2001; Hill & Stull, 1987; Ubando, 2016). Masculinity is a risk factor for
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vulnerability (Möller-Leimkühler, 2003); whereas, femininity leads to increased vulnerability
and subsequently increased symptom reporting.
An important limitation involves the generalizability of the study results. Students not included
in the OSDUHS data collection process were those enrolled in private schools, those who were
home-schooled, those that were on military bases, those in First Nations communities, those
institutionalized for correctional or health reasons, transient populations such as the homeless,
and those in remote northern regions of Ontario (Boak et al., 2016). Some of these excluded
groups, for example, those institutionalized for correctional reasons and transient populations,
such as the homeless, often contain an especially large number of people with mental health
issues, such as ADHD (Edidin, Ganim, Hunter, & Karnik, 2012). However, the coverage error
depends upon the difference in substance use and mental health status between those surveyed
and those not surveyed, and the size of the group not captured due to the design of the study
(Boak et al., 2016). The presence of internalizing problem, externalizing problem, ADHD
symptoms, and substance use may be significantly higher in the excluded groups than those in
the sampled population; yet if the size of the excluded groups is small relative to the total
population, the bias is usually minimal (Boak et al., 2016). Those excluded from the survey’s
target population represent a small proportion of 8% of the Ontario student population; hence,
the vast majority of Ontario adolescents were represented by the OSDUHS (Boak et al., 2016).

5.4 Implications and Directions for Future Research
Despite these limitations, this study has increased understanding of the relationship between selfreported ADHD symptoms and substance use while controlling for SES, internalizing and
externalizing problems, which are covariates that have not been controlled for or studied
altogether in the past Ontario studies. In addition, this study produced supportive evidence on
relatively high prevalence of self-reported ADHD symptoms among youth (Green et al., 2019;
Sonnby et al., 2011). Furthermore, this study adds to research that found that females selfreported ADHD symptoms more than males (Madruga et al., 2012; Polanczyk et al., 2010;
Sonnby et al., 2011), as well as studies that indicate that females with ADHD symptoms had
increased risk of substance use, but not their male counterparts (Elkins et al., 2018; Galéra et al.,
2005; Sihvola et al., 2011). Speculations on why females with ADHD symptoms had a higher
risk of substance use than females without self-reported ADHD symptoms could be that females
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are typically more school and peer oriented than males; therefore, females with inattention
symptoms may be outcasts for not conforming to gender norms (Elkins et al., 2011) leading them
to use tobacco cigarettes and cannabis as a way to cope. However, more research in this area is
needed to understand why females with self-reported ADHD symptoms had a higher risk of
substance use.
Future studies could conduct a psychiatric assessment of a similar cohort of participants who
self-report for ADHD symptoms on the ASRS-v1.1 Screener, in order to validate the results from
this study, as the use of symptom screeners has resulted in a larger proportion of self-reported
ADHD symptoms, especially in females. Although both Adler et al. (2012) and Green et al.
(2019) presented validation studies on the ASRS-v1.1 Screener in adolescents, Green et al.
(2019) noted that this was just initial evidence for reliability and validity of this measurement
tool. Furthermore, Green et al. (2019) studied two high achieving school districts with limited
racial and ethnic diversity; both districts participating in the study had state test passage rates
substantially higher than state or national averages (approximately 90%). Adler et al. (2012)
validated the ASRS-v1.1 Screener in outpatients that met the DSM-IV-TR criteria for primary
diagnosis of ADHD. It is important to note that they studied a very small sample of 88
adolescents (76.1% male) and 73.9% were receiving medication for ADHD, which limits
generalizability of their results (Adler et al., 2012).
Future studies could further test the sensitivity and specificity to measure the degree of overlap
between screening tools and actual psychiatric diagnoses. Prospective follow-up studies of those
who screened for ADHD symptoms may lend to the validation of ASRS-v1.1 Screener as a
predictor of ADHD, as well as ADHD as a co-occurring factor with internalizing and
externalizing problems. This process could also be repeated for the other screeners utilized in
this study to validate screeners that measure internalizing problem and externalizing problem
against clinical diagnoses.
These results warrant future studies to explore the findings of this study. Specifically, knowing
what is being captured by the ASRS-v1.1 Screener and why youth are reporting these symptoms
at such high rates is important. Furthermore, these future studies should focus on why females
are self-reporting such high rates of these symptoms compared to males. Literature indicates that
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females are more likely to have the primarily inattentive subtype of ADHD compared to males;
however, these consequences are less often studied (Elkins, et al., 2018).
In the context of these limitations, the results of the current study warrant further research
measuring risk and resiliency factors of ADHD symptoms and more research on substances such
as stimulants within this context are necessary.

5.5 Conclusions
Overall, a large proportion (20.22%) of Ontario students in grades 9 through 12 self-reported
symptoms of ADHD; 16.42% of males reported ADHD symptoms and 24.06% of females
reported ADHD symptoms. A few studies using the same ASRS measure also found that more
females recorded symptoms of ADHD than males (Madruga et al., 2012; Polanczyk et al., 2010;
Sonnby et al., 2011). Sonnby et al. (2011) found that 18.4% of males self-reported ADHD
symptoms and 23.5% of females self-reported ADHD symptoms.
The prevalence of ADHD symptoms uncovered in this study could be much larger than previous
reported Canadian ADHD statistics because of the measure used to identify ADHD symptoms.
Furthermore, youth are experiencing more mental health issues pertaining to internalizing
problems; symptoms of anxiety and depression and functional somatic symptoms have
significantly increased from 1981 onward and the increase of these symptoms were higher in
females than in males (Blomqvist et al., 2019). Future studies should explore the findings of this
study by identifying what is being captured by the ASRS-v1.1 Screener and why youth are
reporting these symptoms at such high rates. Moreover, these studies should also focus on why
females self-reported these symptoms at higher rates compared to males.
Results from the regression analyses indicated that self-reported ADHD symptoms significantly
increased risk of tobacco cigarette use and stimulant use for males and significantly increased
risk of alcohol use, tobacco cigarette use, cannabis use, and stimulant use for females in the
unadjusted models. However, after accounting for SES, internalizing problem, and externalizing
problem, ADHD symptoms only significantly increased the risk of tobacco cigarette use and
cannabis use in females. Controlling for covariates and comparing unadjusted to adjusted
models, this study provided evidence on the effect of ADHD symptoms on substance use. If only
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unadjusted models were examined, conclusions would be that ADHD symptoms leads to most
types of substance use in females and that ADHD symptoms leads to some types of substance
use in males. However, after adjusting for covariates, it is clearer that internalizing problem and
externalizing problem greatly impact substance use (while SES is only highly related to regular
alcohol use in males), and ADHD symptoms are only related to tobacco cigarette use and
cannabis use in females.
Lastly, due to its limitations, findings from this study have to be interpreted cautiously as the use
of symptom screeners may have resulted in a large proportion of self-reported ADHD symptoms,
especially in females.
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Appendices
Appendix 1: ASRS-v1.1 Screener
Questions:
Never
In the LAST 6 MONTHS,
how often did you have
trouble wrapping up the final
details of a project, once the
challenging parts had been
done?
In the LAST 6 MONTHS,
how often did you have
difficulty getting things in
order when you had to do a
task that required
organization?
In the LAST 6 MONTHS,
how often did you have
problems remembering
appointments or obligations
(thing you had to do)?
In the LAST 6 MONTHS,
when you had a task that
required a lot of thought,
how often did you avoid or
delay getting started?
In the LAST 6 MONTHS,
how often did you fidget or
squirm with your hands or
feet when you had to sit
down for a long time?
In the LAST 6 MONTHS,
how often did you feel overly
active and compelled to do
things, like you were driven
by a motor?

Rarely

Sometimes Often

Very Often
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Appendix 2: K6 Screener
In the
All of the
LAST 4
time
WEEKS,
about how
often did
you feel…
Nervous
Hopeless
Restless or
fidgety
So
depressed
(sad) that
nothing
could cheer
you up
That
everything
was an
effort
Worthless

Most of the Some of
time
the time

A little of
the time

None of
the time
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Appendix 3: Antisocial Behaviour Index

103

Curriculum Vitae
Name:

Shannon Wong

Post-secondary
Education and
Degrees:

Western University
London, Ontario, Canada
2013-2017 Honours Bachelor of Science Specialization in Psychology
Western University
London, Ontario, Canada
2017-2020 Master of Science in Epidemiology and Biostatistics

Honours and
Awards:

Deans Honours List
2013-2017

Related Work
Experience:

Graduate Research Assistant
Western University
Western Centre for Public Health and Family Medicine
2017-2020

Poster
Presentations:

Undergraduate Thesis Presentation Day
Role of Autonomic Signals in Affective Constituents of Familiarity
April 2017

